As filed with the Securities and Exchange Commission on January 11, 2000
Registration No. 333-90877
================================================================================
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
AMENDMENT NO. 1 TO
FORM SB-2
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933,
AS AMENDED
-----------
HEALTHLINK INTERNATIONAL, INC.
--------------------------------------------
(Name of small business issuer in its charter)
<TABLE>
<CAPTION>
<S> <C> <C>
Nevada 6324 88-0331113
------ ---- ----------
(State or other jurisdiction of (Primary Standard Industrial (IRS Employer
incorporation or organization) Classification Code Number) I.D. Number)
</TABLE>
929 Eastwind Drive,, Suite 225
Westerville, Ohio 43081
(614) 890-5100
-----------------------------------------------------------
(Address and telephone number of principal executive offices
and principal place of business)
Nicholas G. Venetis, Chief Executive Officer
HealthLink International, Inc.
929 Eastwind Drive, Suite 225
Westerville, Ohio 43081
(614) 890-5100
-------------------------------------------------------
(Name, address and telephone number of agent for service)
Copies of all communications to:
Gary A. Agron, Esq.
Law Office of Gary A. Agron
5445 DTC Parkway, Suite 520
Englewood, CO 80111
(303) 770-7254
(303) 770-7257 (Fax)
Approximate date of commencement of proposed sale to public: As soon as
practicable after the effective date of the registration statement.
<PAGE>
If this Form is filed to register additional securities for an offering
pursuant to Rule 462(b) under the Securities Act, please check the following box
and list the Securities Act registration statement number of the earlier
effective registration statement for the same offering. |_|
If this Form is a post-effective amendment filed pursuant to Rule 462(c)
under the Securities Act, check the following box and list the Securities Act
registration statement number of the earlier effective registration statement
for the same offering. |_|
If delivery of the Prospectus is expected to be made pursuant to Rule 434,
check the following box: |_|
[EXHIBIT INDEX LOCATED PAGE _____ OF THIS FILING]
<TABLE>
<CAPTION>
CALCULATION OF REGISTRATION FEE
=======================================================================================================================
Title of Each Class Amount Proposed Proposed Maximum Amount
of Securities To Be Maximum Price Aggregate of
to be Registered Registered Per Unit Offering Price Registration Fee
=======================================================================================================================
<S> <C> <C> <C> <C>
Units consisting of one share of 3,000,000 $3.00 $ 9,000,000 $ 2,655
common stock, $.001 par value, Units
and one common stock purchase
warrant...............................
Common stock purchase warrants 3,000,000 $-0- $ -0- $ -0-
included in the units (1)............. Warrants
Common stock, $.001 par value,
underlying common stock purchase 3,000,000 $5.00 $15,000,000 $ 4,425
warrants (1).......................... Shares
Total $24,000,000 $ 7,080 (2)
=======================================================================================================================
</TABLE>
(1) Pursuant to Rule 416 of the Securities Act of 1933, as amended, the number
of shares issuable upon exercise of the Warrants is subject to adjustment
in accordance with the anti-dilution provisions of such Warrants.
(2) Previously paid.
The Registrant hereby amends the Registration Statement on such date or
dates as may be necessary to delay its effective date until the Registrant shall
file a further amendment which specifically states that this Registration
Statement shall thereafter become effective in accordance with Section 8(a) of
the Securities Act of 1933, or until the Registration Statement shall become
effective on such date as the Commission, acting pursuant to said Section 8(a),
may determine.
ii
<PAGE>
Subject to completion dated January __, 2000
3,000,000 Units
HEALTHLINK INTERNATIONAL, INC.
[LOGO]
We are offering a minimum of 1,000,000 units and a maximum of 3,000,000
units of our securities, on a best efforts basis without the assistance of an
underwriter. Each unit consists of one share of common stock and one redeemable
common stock purchase warrant, for $3.00 per unit. The common stock and warrants
will trade separately and not as units.
Until 1,000,000 units are sold, all funds received will be placed in a
non-interest bearing escrow account. If 1,000,000 units are not sold within 90
days from the date of this prospectus, unless we extend the offering for up to
60 days, all funds will be returned to the investors without interest.
See "Risk Factors" beginning on page 7 to read about factors you should
consider before buying our units.
Neither the Securities and Exchange Commission nor any state securities
commission has approved or disapproved of these securities or passed upon the
adequacy or accuracy of this prospectus. Any representation to the contrary is a
criminal offense.
Per Unit Minimum Maximum
-------- ------- -------
Public offering price . . . . . . $3.00 $3,000,000 $ 9,000,000
Underwriting discounts
and commissions . . . . . . . . $0.30 $ 300,000 $ 900,000
Proceeds to HealthLink
International, Inc. . . . . . .$2.70 $2,700,000 $ 8,100,000
The date of this prospectus is ______________ , 2000.
<PAGE>
The information in this prospectus is not complete and may be changed. We
may not sell these securities until the registration statement filed with the
Securities and Exchange Commission is effective. This prospectus is not an offer
to sell these securities and we are not soliciting an offer to buy these
securities in any state where the offer or sale is not permitted.
TABLE OF CONTENTS
Page
----
Prospectus Summary...................................................... 3
Summary Financial Data.................................................. 6
Risk Factors............................................................ 7
Use of Proceeds......................................................... 12
Dividend Policy......................................................... 12
Dilution................................................................ 13
Capitalization.......................................................... 14
Selected Financial Data................................................. 15
Our Plan of Operation................................................... 16
Our Business............................................................ 17
Our Management.......................................................... 25
Our Principal Stockholders.............................................. 28
Related Party and Other Material Transactions........................... 28
Description of Our Securities........................................... 29
Plan of Distribution.................................................... 31
Legal Matters........................................................... 32
Experts................................................................. 32
Additional Information.................................................. 32
Financial Statements.................................................... F-1
2
<PAGE>
PROSPECTUS SUMMARY
Our Business
We offer benefit savings plans which allow our plan members to obtain
discounts of 25% or more off the prices of healthcare products and services,
including the services of 450,000 physicians, 6,500 hospitals and 55,000
ancillary healthcare providers, such as dentists, chiropractors, hearing and eye
care specialists, nurses and counselors. Our members access these healthcare
products and services by presenting discount health cards purchased from us to
the healthcare provider.
Our Market Opportunity
We believe that our emphasis on discount health services, which are offered
under our benefit savings plans, address two significant concerns in the
healthcare industry: medical cost containment and the rising number of people
who are uninsured or underinsured. In 1997 the U.S. Census Bureau reported that
approximately:
* 43 million Americans, or approximately 16% of the population, had no
health insurance, and most Americans lacked insurance coverage for one
or more "ancillary" healthcare services, such as dental, chiropractic,
hearing care, eye care and pharmaceutical services.
* 4.8 million Americans with household incomes of $75,000 or more and
approximately 5.7 million Americans with incomes between $50,000 to
$75,000 were uninsured.
3
<PAGE>
We believe that our medical discount cards provide a low-cost,
non-insurance alternative to:
o those seeking to reduce healthcare costs not covered by insurance;
o those desiring to fill in the coverage gaps in their current policies;
o those who are unable to obtain healthcare insurance due to their
medical history, age or occupation; and
o those that may be underinsured because of restrictions or provisions
within their managed care plans.
Our Strategy
Our strategy is to:
o expand our marketing capabilities;
o increase the number and content of our benefits savings plans;
o increase sales of our benefit savings plan programs; and
o start up or acquire other companies engaged in healthcare or related
industries.
Our Offices
Our corporate offices are located at 929 Eastwind Drive, Suite 225,
Westerville, Ohio 43081, telephone number (614) 890-5100. Our Web site is
located at www.healthlinkintl.com. Information contained in our Web site should
not be considered a part of this prospectus.
The Offering
Securities offered . . . . . . 3,000,000 units, each unit consisting of one
share of common stock and one redeemable
common stock purchase warrant. The common
stock and warrants will trade separately and
not as units. Each warrant is exercisable to
purchase one share of common stock at $5.00
per share until December 31, 2002. We may
call the warrants for redemption on 30 days'
notice if our common stock price exceeds
$6.00 per share for ten consecutive trading
days.
4
<PAGE>
Securities outstanding
prior to the offering . . . . 11,839,827 shares of common stock
Securities to be outstanding
after the offering . . . . . 14,839,827 shares of common stock and
3,000,000 common stock purchase warrants
5
<PAGE>
SUMMARY FINANCIAL DATA
The following tables set forth financial information derived from our
audited financial statements for the year ended December 31, 1998 and other
financial information derived from our unaudited financial statements for the
nine months ended September 30, 1999 and 1998. We commenced our current
operations in September 1998.
<TABLE>
<CAPTION>
Nine Months Ended September 30 Year Ended December 31
1999 1998 1998
---------- --------- ------------------
<S> <C> <C> <C>
Statement of Operations Data
- ----------------------------
Revenue . . . . . . . . . . . $ 207,998 $ 2,290 $8,242
Cost of sales . . . . . . . . $ 175,581 $ 1,922 $6,917
Operating expenses . . . . . . $ 186,371 $ 500 $1,250
Research and development . . . $ 120,000 $ -- $ --
Net income (loss). . . . . . . $(273,954) $ (132) $ 75
Weighted average
number of shares
outstanding . . . . . . . . . 11,474,310 11,474,310 11,474,310
Net income (loss) per share. . $ (.02) $ -- $ --
Actual As Adjusted(1)
------ --------------
Balance Sheet Data at September 30, 1999:
- ----------------------------------------
Working capital . . . . . . . . . . . . . . $ (34,050) $7,839,737
Total assets . . . . . . . . . . . . . . . $1,014,287 $8,814,287
Total liabilities . . . . . . . . . . . . . $ 34,100 $ 34,100
Stockholders' equity . . . . . . . . . . . $ 980,187 $8,780,187
</TABLE>
(1) As adjusted to reflect the sale of 3,000,000 units offered by this
prospectus at $3.00 per unit and the application of the net proceeds.
6
<PAGE>
RISK FACTORS
This offering involves a high degree of risk. You should carefully consider
the risks and uncertainties described below and the other information in this
prospectus before deciding whether to invest in our securities. If any of these
risks occur, our business, results of operations and financial condition could
be harmed. This could cause the trading price of our securities to decline, and
you might lose part or all of your investment.
Our operating history is extremely limited; we may have future losses and may
need more capital.
We commenced our current business operations in September 1998, have
incurred losses since that date and have not generated significant revenue.
Accordingly, we have no operating history upon which an investor can evaluate
us, and our prospects are subject to risks and uncertainties encountered by
early- stage companies that operate in a constantly evolving market, such as the
healthcare market.
Our limited operating history and the uncertainty of the evolving
healthcare market make any prediction of our future results of operations
difficult or impossible. We expect to increase considerably our operating
expenses in the future, particularly by expanding our marketing capabilities. As
a result, we may incur losses and may need to raise additional capital. We
cannot assure that we will be able to raise additional capital, and we do not
know what the terms of any capital raising would be. Any future sale of our
equity securities would dilute the ownership and control of our stockholders and
could be at prices substantially below the offering price of our units.
7
<PAGE>
We may be liable for medical malpractice claims which could result in losses for
our business.
Physicians and other medical entities have become increasingly vulnerable
to lawsuits alleging medical malpractice. While we do not practice medicine or
control any provider's practice of medicine, we may become a party to
malpractice litigation anyway. We may also be exposed to claims for personal
injuries as a result of the incorrect preparation or packaging of prescriptions.
We take precautions to avoid these claims, such as by seeking indemnification
from providers, but we cannot assure that our precautions will prove adequate.
Because we do not render medical services, we cannot obtain malpractice
insurance. We do not maintain errors and omissions insurance, but we maintain
general liability insurance which provides coverage for property damage,
business liability and medical payments.
We must comply with government regulations which are costly and may limit our
operations.
The delivery of our discount health care products and services is subject
to federal, state and local regulation, including:
o the prohibition of business corporations from providing medical care;
o the fraud and abuse provisions of the Medicare and Medicaid statutes;
o state laws that prohibit referral fees and fee splitting; and
o regulations applicable to insurance companies and organizations that
provide healthcare services.
In addition, statutes and regulations applicable to other healthcare
organizations with which we may contract, such as patient freedom of choice
rights and anti-discrimination rights, may force other organizations to withdraw
as our providers. Compliance with these statutes and regulations are costly and
may limit our operations.
We may not be able to successfully compete with other cost containment
organizations for employee benefit expenditures.
We compete with other medical cost-containment organizations, such as
preferred provider organizations, HMOs and insurance companies, for a portion of
employee medical benefit expenditures made by employers. Most of these
competitors have had longer operating histories and have greater financial,
marketing and other resources than we.
Our management is inexperienced and may not be able to manage our growth.
Our management team has worked together for only a short time and none of
our executive officers has extensive experience managing a business enterprise
similar to ours. Any growth we experience will place a significant strain on our
management and financial resources. Any inability of our management to manage
growth effectively could increase our operating expenses and impair our
marketing efforts.
8
<PAGE>
If government regulations regarding network marketing companies are changed,
interpreted or enforced in a manner adverse to our network marketer, our revenue
could be reduced.
A significant portion of our revenue is generated through sales of discount
medical services to members of Purchase Plus, a network marketing company
affiliated with us. Network marketing companies are subject to extensive
governmental regulation, including federal and state regulation regarding
network marketing plans and the offer and sale of business franchises, business
opportunities and securities. Any change in legislation or regulations or the
noncompliance with these regulations by our network marketer could reduce its
membership and thereby reduce our revenue.
Failure of third parties to achieve Year 2000 compliance could adversely affect
our business.
Many currently installed computer systems and software products are coded
to accept only two-digit entries to represent years in the date code field.
Computer systems and products that do not accept four-digit entries will need to
be upgraded or replaced to accept four-digit entries to distinguish years
beginning with 2000 from prior years. We believe our computer systems and those
of our healthcare providers are Year 2000 compliant. Any failure of the systems
of third parties with whom we deal to achieve Year 2000 compliance could harm
our business.
If we are not able to sell 1,000,000 units, funds will be returned to investors
without interest and investors will not have had the use of their funds during
a five month period.
We are seeking to sell the units without the assistance of an underwriter
that would generally be retained to purchase the securities directly from us for
resale to the underwriter's clients and other brokerage firms. However, we are
offering the units ourselves, which makes it less likely that the minimum number
of units will be sold. Until we sell the minimum 1,000,000 units, all investor
funds will remain in a non-interest bearing escrow account during the selling
period, which could be up to five months from the date of this prospectus. At
the end of the selling period, if we have not sold 1,000,000 units, the funds
will be returned to investors without interest, and investors will not have had
the use of their funds during the selling period.
9
<PAGE>
Since there is no current market for our common stock, and since we do not have
an underwriter for our offering, purchasers may be unable to sell our common
stock in the future.
There is presently no public market for the common stock and warrants and
no assurance that an active market will develop or be maintained. Accordingly,
there can be no assurance that purchasers will be able to sell their securities
in the future. Since we have no underwriter in the offering, we may be unable to
attract brokerage firms willing to make a market in our securities, which will
further reduce the liquidity of the securities.
We have not registered our warrants in a number of jurisdictions, and therefore,
holders may not be able to exercise them.
The warrants are not convertible or exercisable unless, at the time of
exercise, we have a current prospectus covering the shares of common stock
issuable upon exercise of the warrants and these shares have been registered,
qualified or deemed to be exempt under the securities laws of the
warrantholders' state of residence. There can be no assurance that we will have
or maintain a current prospectus or that the securities will be qualified or
registered under any state laws.
We cannot assure that our securities will trade on the Electronic Bulletin
Board. Even if our securities trade on the Electronic Bulletin Board, it may be
difficult to sell our securities.
We will be unable to apply for listing of our securities on the Electronic
Bulletin Board until we sell the minimum 1,000,000 units and until the proceeds
from the sale have been deposited in escrow. Accordingly, we cannot assure that
our securities will be accepted for listing on the Electronic Bulletin Board. If
the securities are not accepted for listing, then no public market will develop
for resale of the securities, and investors would be unable to sell the
securities offered by this prospectus. If the securities are listed for trading
on the Electronic Bulletin Board, investors may find it more difficult to
dispose of or to obtain accurate quotations for the market value of our
securities compared to securities which trade on the Nasdaq system or on
national stock exchanges.
Forward-looking statements may be unreliable.
Many statements made or incorporated by reference in this prospectus are
"forward-looking statements" and include statements about:
o our ability to market our benefit savings plans;
o our ability to obtain discounted products and services from third
party providers;
o the anticipated growth in the number of older Americans and their
healthcare needs;
o competitiveness of the healthcare cost containment industry;
o our strategy to expand revenue and generate earnings;
o other statements that are not historical facts.
10
<PAGE>
When used in this prospectus, the words "anticipate", "believe", "expect",
"estimate", "intend" and similar expressions are generally intended to identify
forward-looking statements. Because these forward-looking statements involve
risks and uncertainties, there are important factors that could cause our actual
results to differ materially from those expressed or implied by these forward
forward-looking statements, including:
o changes in the healthcare industry;
o steps taken by current and future competitors;
o the extent to which we are able to develop and expand markets for our
benefit savings plans;
o the time and expense involved in our development activities; o the
level of demand for, and market acceptance of, our benefit savings
plans;
o changes in our business strategy;
o other factors discussed in the "Risk Factors" section and elsewhere in
this prospectus.
11
<PAGE>
USE OF PROCEEDS
After payment of underwriting commissions and other expenses of the
offering, the net proceeds of the offering are estimated to be $2.4 million if
the minimum number of units is sold and $7.8 million if the maximum number of
units is sold. We expect to use the net proceeds over the next 12 months
approximately as follows:
Assuming minimum proceeds of $2.4 million:
o $0.7 million for marketing and advertising expenses;
o $0.4 million to increase our product and service providers;
o $0.25 million for general, administrative and other operating
expenses;
o $0.54 million to fund our commitment to Longport, Inc. through
December 2000; and
o $0.51 million reserved for working capital and to cover overages in
the above estimated expenditures.
Assuming maximum proceeds of $7.8 million:
o $2.5 million for marketing and advertising expenses;
o $3.0 million to increase our product and service providers;
o $0.75 million for general, administrative and other operating
expenses;
o $0.54 million to fund our commitment to Longport, Inc. through
December 2000; and
o $1.01 million reserved for working capital and to cover any overages
in the above estimated expenditures.
Proceeds not immediately needed will be invested in bank certificates of
deposit, treasury bills, insured bank deposits or similar investments.
DIVIDEND POLICY
We have never paid dividends on our common stock and do not intend to pay
dividends in the foreseeable future. Instead, we will retain any earnings to
finance the expansion of our business and for general corporate purposes.
12
<PAGE>
DILUTION
At September 30, 1999, the net tangible book value of our outstanding
shares of common stock was approximately $906,400, or $.08 per share. "Net
tangible book value" per share represents the total amount of our tangible
assets, less the total amount of our liabilities, divided by the number of
shares of common stock outstanding. Without taking into account any changes in
net tangible book value after September 30, 1999, other than to give effect to
the sale of all 3,000,000 shares of common stock offered hereby at a public
offering price of $3.00 per share, less underwriting discounts and commissions
and estimated costs of the offering, our net tangible book value at September
30, 1999 would have been approximately $8.8 million, or $.61 per share. This
assumes that the warrants included in the units have no value. This per share
value represents an immediate increase in net tangible book value of $.53 per
share of common stock to our existing stockholders and an immediate dilution of
$2.39 per share to new investors. "Dilution" per share represents the difference
between the price to be paid by the new stockholders and the net tangible book
value per share of common stock immediately after this offering.
The following table illustrates this per share dilution:
Public offering price per share . . . . . . . . . $3.00
Net tangible book value per share
before the offering . . . . . . . . . . . . $.08
Increase in net tangible book value
per share attributable to new investors
purchasing in the offering . . . . . . . . $.53
Net tangible book value per share
after the offering . . . . . . . . . . . . . . . $ .61
-----
Dilution per share to new investors. . . . . . . . $2.39
=====
The following table sets forth the maximum number of shares of common stock
that may be purchased, the total consideration to be paid and the average price
per share paid by our existing stockholders as of September 30, 1999 and new
investors purchasing shares of common stock offered hereby:
<TABLE>
<CAPTION>
Shares Purchased Total Consideration Average
---------------- ------------------- Price
Number Percentage Amount Percentage Per Share
------ ---------- ------ ---------- ---------
<S> <C> <C> <C> <C> <C>
New investors .............. 3,000,000 20.7% $9,000,000 93.1% $ 3.00
Existing stockholders ...... 11,474,310 79.3% $ 664,743 6.9% $ .06
---------- ----- ---------- -----
TOTALS ..................... 14,474,310 100.0% $9,664,743 100.0%
========== ===== ========== =====
</TABLE>
13
<PAGE>
CAPITALIZATION
The following table sets forth our historical and as adjusted
capitalization as of September 30, 1999, after deducting underwriting discounts
and commissions and estimated offering expenses. As adjusted capitalization
reflects the sale of the maximum 3,000,000 units offered hereby at an offering
price of $3.00 per share and the application of the net proceeds.
<TABLE>
<CAPTION>
September 30, September 30,
1999 1999
Actual As Adjusted
------------- -------------
<S> <C> <C>
Stockholders' equity:
Preferred stock, 1,000,000 no par value shares
authorized, no shares issued ............................ $ -- $ --
Common stock, 100,000,000 $.001 par
value shares authorized, 11,474,310
shares outstanding, 14,474,310 shares
outstanding, as adjusted ................................ 11,474 14,474
Additional paid-in capital ................................ 653,269 8,450,269
Retained earnings (deficit) ............................... (275,006) (275,006)
Accumulated other comprehensive income .................... 590,450 590,450
----------- -----------
Total stockholders' equity ....................... 980,187 8,780,187
----------- -----------
Total capitalization ............................. $ 980,187 $ 8,780,187
=========== ===========
</TABLE>
14
<PAGE>
SELECTED FINANCIAL DATA
The following tables set forth financial information derived from our
audited financial statements for the year ended December 31, 1998 and other
financial information derived from our unaudited financial statements for the
nine months ended September 30, 1999 and 1998.
<TABLE>
<CAPTION>
Nine Months Ended September 30 Year Ended December 31
1999 1998 1998
------------ ------------ ----------------------
Statement of Operations Data
- ----------------------------
<S> <C> <C> <C>
Revenue .................................... $ 207,998 $ 2,290 $ 8,242
Cost of sales .............................. $ 175,581 $ 1,922 $ 6,917
Operating expenses ......................... $ 186,371 $ 500 $ 1,250
Research and development ................... $ 120,000 $ -- $ --
Net income (loss) .......................... $ (273,954) $ (132) $ 75
Weighted average
number of shares
outstanding ............................... 11,474,310 11,474,310 11,474,310
Net income (loss) per share ................ $ (.02) $ -- $ --
</TABLE>
Actual As Adjusted(1)
------ --------------
Balance Sheet Data at September 30, 1999:
- -----------------------------------------
Working capital .................................. $ (34,050) $ 7,839,737
Total assets ..................................... $ 1,014,287 $ 8,814,287
Total liabilities ................................ $ 34,100 $ 34,100
Stockholders' equity ............................. $ 980,187 $ 8,780,187
(1) As adjusted to reflect the sale of 3,000,000 units offered hereby at $3.00
per unit and the application of the net proceeds.
15
<PAGE>
OUR PLAN OF OPERATION
The following discussion of our plan of operation should be read in
conjunction with our financial statements, the notes related thereto, and the
other financial data included elsewhere in this prospectus. The discussion
contains forward-looking statements that reflect our plans, estimates and
beliefs. Our actual results could differ materially from those discussed in the
forward-looking statements. Factors that could cause or contribute to these
differences include, but are not limited to, those discussed below and elsewhere
in this prospectus, particularly in "Risk Factors."
We are a start-up company, having commenced operations in September 1998.
To date, our activities have been limited to drafting our business plan,
organizing our company, developing our initial relationships with discount
healthcare providers, hiring personnel, opening our offices and developing our
initial marketing plans.
Results of Operations
Net sales increased to $207,998 for the nine months ended September 30,
1999 compared to $2,290 for the prior year. Gross profit increased by
approximately $32,049 from $368 in 1998 to $32,417 for 1999. Our gross profit is
expected to increase in the future as a result of our agreement with Purchase
Plus Buyers' Group, Inc., which is discussed below.
We lost $273,954 and $132 for the nine months ended September 30, 1999 and
1998, respectively, and we expect to incur additional losses for the remainder
of 1999 and into 2000 as a result of additional costs we expect to incur
associated with marketing, hiring of personnel and instituting our business
plan.
Significant operating categories for the nine months ended September 30,
1999 included office rent ($2,851), travel ($3,563), consulting services
($81,661), writeoff of a loan to an unaffiliated corporation ($88,000) and
compensation expense for stock issued to employees ($5,710). We expect our
operating expenses to increase in future quarters as we continue to develop our
operating plan and expand our marketing and sales efforts.
Our research and development expenses of $120,000 for the nine month period
ended September 30, 1999 reflect the terms of our June 1999 technology and
marketing agreement with Longport under which we have agreed to provide Longport
with $5 million over a five-year period to fund technology enhancements for
Longport's digital scanner in exchange for 10% of the gross revenue generated
from the scanner enhancements and related new technology until 2009. The $5
million of funding is to be paid at the rate of $360,000 for the first year,
$720,000 the second year, $1,440,000 for the third and fourth years and $100,000
per month during the fifth year until the balance of $5 million is paid. We also
have the right to finance Longport's cost of producing its scanners in exchange
for 50% of the gross revenue generated by those scanners.
In April 1999 we purchased 350,000 shares of Longport common stock for
$1.00 per share. The quoted market price of these shares at September 30, 1999
was $2.69 per share, or a total of $940,450, representing an unrealized gain at
September 30, 1999 of $590,450. The unrealized gains and losses are reported as
a separate component of our Statement of Stockholders' Equity, net of tax. Since
we invested in the Longport stock, we have adjusted our financial statements
monthly to reflect the current quoted market value of the shares.
If we raise the minimum net proceeds of $2.4 million, we intend to increase
our product and service providers, emphasizing discount healthcare providers and
spending on marketing and advertising, with emphasis upon our Internet
operations. We will also continue to develop an in-house marketing staff and
maintain our commitment to Longport, Inc.
If we raise additional net proceeds in excess of $2.4 million, we will
concentrate most of our additional spending on further increasing our product
and service providers and on further expanding our marketing activities. In this
event, we will begin to add non-healthcare providers, including those that offer
services to small businesses, such as tax preparers, equipment lessors and
business insurers. We will also seek to acquire other companies engaged in
healthcare and related industries and ramp up our marketing activities to
support our additional activities. To date we have not entered into any
agreements, arrangements or understandings with respect to any acquisitions or
business combinations.
16
<PAGE>
We currently expect that our available cash resources combined with the net
proceeds from the offering will be sufficient to meet our anticipated capital
rquirements for at least the 12 months following our receipt of the minimum net
proceeds of this offering of $2.4 million.
We do not expect to incur any significant costs to address the impact of
the so-called Year 2000 problem. The Year 2000 problem concerns the inability of
information systems, primarily computer software programs, to properly recognize
and process date-sensitive information as the Year 2000 approaches. We believe
that our present systems and those of our healthcare providers are Year 2000
compliant.
Liquidity and Capital Resources
In July 1999 we entered into an agreement with Purchase Plus, a network
marketing company owned by Everett Eugene Armold, under which Purchase Plus
agreed to purchase 100,000 of our discount cards for $40 per card in 2000 and
will prepay the first 10,000 cards in consideration of our agreement not to
offer our discount cards to any other network marketing organization. Everett
Eugene Armold, who owns Purchase Plus, is the husband of Cleone W. Armold, one
of our directors. Two of our officers and directors, Ms. Armold and Mr.
Pedersen, are also officers and directors of Purchase Plus.
During the nine months ended September 30, 1999, our cash obligations were
funded by capital contributions from a shareholder. In October 1999, we entered
into a letter of credit with Simba Financial, Incorporated providing for cash
advances of up to $500,000 to finance our operating expenses and working capital
requirements. Any amounts advanced under the line of credit will bear interest
at 10% per annum and are due on December 31, 2000. At September 30, 1999, no
sums were advanced under the letter of credit. Mr. Armold is a principal
stockholder of Simba.
Operating activities used $146,144 of cash for the nine months ended
September 30, 1999, which was primarily a result of the net loss for the period.
Investing activities used $437,925 of cash for the nine months ended
September 30, 1999. We invested $350,000 in Longport's securities and made an
$88,000 loan to an unrelated corporation. The loan was not repaid and was
written off during the period.
Financing activities provided $584,119 of cash for the nine months ended
September 30, 1999. Approximately $659,033 was gratuitously contributed to our
capital during the period and we incurred $73,787 of offering costs during the
period.
We have a commitment of approximately $4,880,000 under our technology and
marketing agreement with Longport. No other significant commitments existed as
of September 30, 1999.
OUR BUSINESS
Our History
We were incorporated in Nevada in November 1994 as Commercial Building
Systems, Inc., but were inactive until September 1998 when we commenced our
current operations. We changed our name to HealthLink International, Inc. in
March 1999.
Our Current Operations
Our primary savings product is our HealthLink discount health card, which
allows holders to obtain discounts of approximately 25% or more on purchases of
healthcare products and services through our networks of healthcare providers.
Our discount card provides our members with reduced rates on physician and
hospital services, on ancillary medical services and on a 24-hour information
line staffed by nurses. Our health services networks comprise an aggregate of
approximately 450,000 physicians, 6,500 hospitals and 55,000 other medical
providers who offer ancillary health services and products throughout the United
States, such as:
o dental care;
o chiropractic services;
o hearing care;
o eye care; and
o pharmacy plans.
17
<PAGE>
Our physicians and hospital providers offer a full range of primary medical
services, as well as:
o plastic and cosmetic surgery;
o infertility services;
o psychiatric services; and
o services related to chemical dependency.
Substantially all of our discounted medical products and services are
provided under contracts we have with two network providers: International
MedCare, Inc. and National Administrative Company, Inc.
Our contract with IMC expires October 2000 and is cancellable by either
party on 45 days' notice. IMC provides us with networks of physicians, hospitals
and other healthcare providers that offer healthcare services under our discount
card.
Our contract with NAC expires October 2002 and may be cancelled by either
party on 120 days' notice prior to year end. NAC provides us with networks of
ancillary healthcare providers, including dentists, chiropractors, hearing care
specialists and eye care specialists, as well as other ancillary products,
including pharmacy services, a 24-hour nurse information line and a legal
benefits plan.
To date, all of our revenue has been generated through sales of our
discount medical services to members of Purchase Plus Buyer's Group, Inc.
Purchase Plus is a network marketing company owned by Everett Eugene Armold, who
is married to Cleone W. Armold, a principal stockholder and director of our
company. We anticipate that revenue generated by sales to members of Purchase
Plus will represent a smaller percentage of our total revenue in the future as
we expand our marketing efforts.
We believe that our emphasis on discount health services addresses two
significant concerns in the healthcare industry: cost containment and the rising
number of people who are uninsured or underinsured. We believe that our discount
cards provide a low-cost, non-insurance alternative to individuals who are
seeking to reduce their out-of-pocket healthcare costs not covered by insurance
or who are unable to obtain healthcare insurance due to their medical history,
age or occupation. For an annual fee of $99, our members obtain discounts of
approximately 25% or more off the retail, or usual and customary, charges of
participating healthcare providers. Acceptance in our program is unrestricted,
and our cards can be used to cover the member's entire immediate family.
Our Strategy
Our strategy is to:
o further develop and expand our marketing capabilities by:
o increasing the content currently available on our bilingual
Internet Web site;
o developing programs to offer our benefit savings plans directly
to affinity groups, such as large corporations, small business
and trade associations and charitable organizations; and
o expanding our in-house marketing staff.
o develop benefit savings plans for small businesses which would include
access to discounts on tax preparation, equipment leasing and business
insurance;
o increase our benefit savings plan sales by adding non-medical related
discounted products and services, such as accidental death coverage
and ambulance services; and
o start up or acquire other companies engaged in healthcare or related
industries following the offering.
We intend to use proceeds of the offering to develop benefit savings plans
directly to affinity groups and to expand our in-house marketing staff.
Accordingly, we will not institute these strategies until the fourth quarter of
2000. We will, however, develop our small business benefit savings plans and
expand their products and services commencing in the second quarter of 2000.
We will seek to enter into agreements with other networks of providers that
offer primary, ancillary and other discounted services and products not
currently offered by us. We intend to monitor the needs of members for
additional services that might be available. We also intend to monitor the
market for new medical benefits products that might be included with our
healthcare discount cards.
18
<PAGE>
Healthcare Overview
In recent years the cost of healthcare products and services has increased
at a greater rate than inflation. These increasing costs have led to limitations
on reimbursement from insurance companies, HMOs and government sources and have
generated demand for products and services designed to control healthcare costs.
Many employers have responded to the increased cost of providing health
insurance to their employees by reducing or eliminating available insurance
coverage and/or by requiring employees to contribute heavily to premiums,
especially for family members. As a result, the U.S. Census Bureau reported that
in 1997 approximately 43 million Americans, or approximately 16.1% of the
population, had no health insurance, and most Americans lacked insurance
coverage for one or more ancillary healthcare services. At the same time
according to the July 1997 issue of Managed Healthcare, the July 1997 issue of
Employee Benefit News and an October 1996 issue of the Wall Street Journal.
o the average price of prescriptions in the United States has risen from
$12 to $27 over the past ten years and continues to rise at the rate
of 4% per year;
o the average senior citizen takes 3.3 medications every day;
o 60% of all Americans require corrective lenses; 90% of Americans over
the age of 43 require corrective lenses;
o more than 900,000 Americans require medical assistance while traveling
away from home each year;
o over 33 million Americans are hearing impaired, but only approximately
6% purchase hearing aids because they consider the cost prohibitive;
o 19 million Americans use chiropractic services each year;
yet, according to an Associated Press wire story in October 1998, six million
Americans did not take health insurance that was offered at work in 1997.
As a result of the baby boom generation, people over the age of 50
represent the fastest growing segment of the United States population. As the
population ages, more people will need both primary and ancillary healthcare
products and services.
Our Members
Our members generally are part of the following categories of individuals
and organizations:
o uninsured-individuals who cannot or do not wish to incur the expense
of traditional health insurance, especially part-time and temporary
employees, recently graduated students and the self-employed;
o underinsured-individuals covered by a health plan with limited
coverage, high deductibles and/or co-insurance limits, or needing
family coverage;
o insured-individuals seeking providers outside their present health
plans or interested in filling gaps in their coverage;
o uninsurable-individuals who are not eligible for health insurance
because of medical history, profession, lifestyle or other reasons;
o smaller groups-including small businesses, chambers of commerce,
employers of temporary or part-time personnel and other businesses
seeking affordable health benefits for their employees in order to
promote employee loyalty and differentiate their companies in the
marketplace;
o associations-including service organizations and trade groups seeking
to increase membership and promote member/customer loyalty by
providing or offering a discount health benefit.
Primary Medical Services
We offer a network of 450,000 physicians and 6,500 hospitals that provide a
full range of discounted medical services throughout the United States. Almost
75% of the acute care hospitals in the United States are members of our network,
including some of the better known cardiac and transplant hospitals. Our network
consists of over 200 medical specialties, including:
o chemical dependency;
o counseling and rehabilitation;
o chiropractic care;
o infertility;
o marriage and family counseling;
o nutrition;
19
<PAGE>
o pain management;
o psychiatry;
o psychology;
o plastic surgery;
o podiatry;
o preventative medicine;
o sleep disorder therapy; and
o speech therapy.
In order to obtain discounts from physicians and hospitals, our members
complete a payment pre- authorization process which will make their medical
visit identical to other medical payment plans, such as insurance plans, HMOs
and the like. Members select a provider from our network, make an appointment
and request an estimate of fees for the anticipated procedure. The member then
calls IMC, our contract partner, to arrange for prepayment using a major credit
card. IMC sends the provider a referral guaranteeing payment based upon a "hold"
we have placed on the member's credit card. The member makes no payment to the
provider at the time services are rendered but simply presents his membership
card. The provider bills IMC, and IMC pays the provider and charges the
discounted amount to the member's credit card. The member subsequently receives
a statement of savings indicating the original amount billed, the amount charged
after savings were applied, and the total amount saved.
Ancillary Services
Our HealthLink discount card provides ancillary healthcare services
including:
Dental. Our dental services and products are designed to provide our
members with discounts of 10% to 40% on dental examinations and dental products
from over 14,300 dentists throughout the United States.
Chiropractic. Our chiropractic services are designed to provide our members
with discounts of 20% to 50% on chiropractic examinations and related
chiropractic services from over 4,700 chiropractors throughout the United
States.
Hearing. Our hearing services are designed to provide our members with
discounts starting at 10% on hearing examinations and hearing products from over
1,700 hearing specialists throughout the United States.
Eye Care. Our eye care services are designed to provide our members with
discounts of 20% to 75% on eye examinations, contact lenses, eyeglass frames and
lenses and eye surgery from over 9,100 eye care specialists throughout the
United States.
20
<PAGE>
Pharmacy. Our pharmacy plans include discounts of 20% to 25% on drugs from
over 14,000 mail order pharmacies.
Nurse Information. We provide toll-free telephone access to experienced
registered nurses, 24 hours a day, 365 days per year. Our nurses are an
immediate and reliable source of health and medical information, education and
support.
The purpose of the nurse information service is to give our members
information to assist them in making decisions about their healthcare. In
addition to providing information that may prevent unnecessary trips to the
emergency room, trained nurses assist members in connection with:
o help with minor and emergency situations and general information on
all types of health and medical concerns supported by an audio health
library;
o self-care information and solutions based on physician-approved
guidelines;
o information about prescription and over-the-counter medication usage
and interaction; and
o information on non-medical support groups from a comprehensive
national database.
Legal Services. Our discount card also provides members with discounts for
consumer legal services provided by a network of over 7,000 attorneys throughout
the United States.
Advantages of HealthLink Discount Cards
Advantages to Members. In addition to providing access to healthcare
products and services on a discounted basis, we believe our discount healthcare
cards are attractive to members because of their flexibility and ease of use.
Membership in our healthcare programs is unrestricted and provides benefits to
individuals who, because of their medical history, age or occupation, are unable
to obtain health insurance. The cards cover each person in the member's
immediate family and can be used as often as each participant wishes. In
addition, unlike many insurance or managed care programs, members have no
paperwork or claims to prepare and no waiting periods.
Advantages to Providers and Networks. We believe that physicians, hospitals
and other healthcare providers are attracted to our programs because the
programs increase their customer base. Although members generally pay fees and
charges less than those of non-members, the incremental business from members
offers an additional source of revenue to the providers, with little or no
increase in their overhead costs. In addition, we believe that our programs are
attractive to provider networks because they increase the likelihood that
providers will affiliate with these provider networks in order to have access to
more members.
Advantages to Sponsors. We believe that our discount cards are attractive
to sponsors, that is, organizations with larger memberships or employee bases
that offer healthcare cards to their members or employees. We believe that our
cards assist sponsors in their efforts to attract and retain employees by
enabling them to offer a more complete healthcare benefits package. Similarly,
as competition between HMOs for participants intensifies, we believe that our
cards will enable HMOs to offer a more complete array of potential healthcare
benefits. Due to the low cost of the cards, sponsors may offer them to part-time
employees, who often are not eligible for healthcare benefits offered to
full-time employees. Moreover, because the cards are discount cards and not an
insurance product, sponsors can offer discounts to their employees or members
without bearing any economic risk in excess of the annual cost of the card.
21
<PAGE>
Sales and Marketing
We intend to market our benefit savings plans:
Through Purchase Plus. We have entered into an agreement with Purchase Plus
under which we provide the ancillary benefits portion of our benefit savings
plan to members of Purchase Plus for a set annual fee per member. Purchase Plus
purchases the program from us, adds a service charge for handling and sells the
program directly to its members. Purchase Plus is a network marketing company
with over 15,000 members owned by Everett Eugene Armold, who is married to
Cleone W. Armold, a principal stockholder and director of our company. The
agreement is cancellable by either party on 30 days' notice.
Through the Internet. We have completed the development of English and
Spanish language healthcare benefits Internet Web site at www.healthlinkintl.com
which is accessible to healthcare providers, sponsors and members. Those
accessing the Web site are or soon will be able to review:
o our benefit savings plans;
o a list of our benefits providers and their locations;
o products and services provided by our providers;
o discounts available to members for services and products; and
o special promotions.
In the future, individuals accessing our Web site will be able to purchase one
of our benefit savings plans by filling out an application online.
We also use banner-style advertisements on drkoop.com, a Web site devoted
to providing consumer medical information and the sale of medical products and
services to the public.
By Developing New Programs. By the fourth quarter of 2000, we intend to
develop new benefits savings plans for sale to affinity groups such as large
corporations, small business and trade associations and charitable
organizations. Under an affinity card arrangement, the sponsor would be able to
custom design and place its or our name on the discount card. In either event,
we would provide access to our networks, as well as all required fulfillment
services. We believe that affinity or private label cards will be attractive to
some sponsors because the cards will enable them to more closely identify
themselves with the benefits provided to their member. Moreover, we believe that
the preexisting relationship, or affinity, between the sponsor and its employees
or members will enhance the likelihood that the employee or member will purchase
our card.
Through Our In-house Marketing Staff. By the fourth quarter of 2000, we
intend to establish an in-house marketing staff to market our benefit savings
plans to other large sponsors, such as insurance carriers, third party
administrators, HMOs, preferred provider organizations and unions.
We expect that these sponsors will either fund the healthcare plans on
behalf of their members or employees so that every eligible individual in the
organization becomes a member or offer the plans to their members or employees
as an option where each individual will be responsible for purchasing the plan
discount card and paying the annual fee either directly or through a payroll
deduction plan. We also expect to market the plan directly to members of
sponsors, particularly in cases where a sponsor offers plan benefits as an
unpaid option to its members.
22
<PAGE>
Competition
Our discount healthcare plans compete with the products of various cost
containment marketing organizations for a portion of the health benefit dollars
allocated by various organizations for employee medical benefit programs. These
organizations include:
o preferred provider organizations;
o HMOs;
o insurance companies;
o healthcare membership programs;
o retail pharmacies;
o mail order prescription companies; and
o other ancillary healthcare insurance programs for members and
providers.
With respect to our dental, chiropractic, hearing, eye care and
pharmaceutical products, we compete for sponsors, members and providers,
depending on the geographic area or market, with various entities that have
developed discount membership cards which provide national ancillary medical
benefits coverage, including AT&T, CUC International, and J.C. Penney, and
entities that have developed discount membership cards which provide regional
coverage only. We also compete with various organizations which provide services
and products in specific areas of ancillary healthcare, such as pharmaceutical
services. Most of our competitors have longer operating histories and have
significantly greater financial, marketing and administrative resources than we.
Agreement with Longport
In June 1999, we entered into an agreement with Longport, Inc. under which
we agreed to provide to Longport $5 million over a five-year period to fund
technology enhancements for Longport's digital scanner. The digital scanner is a
portable, high-frequency, ultrasound scanner which captures and reproduces
images of soft tissue at a high resolution down to two centimeters below the
skin, using a laptop computer. Longport received FDA permission to market the
scanner in June 1999.
The $5 million of funding is to be paid at the rate of $360,000 the first
year, $720,000 the second year, $1,440,000 the third and fourth years and
$100,000 per month during the fifth year until the balance of $5 million is
paid. In exchange for this funding, we are to receive 10% of the gross revenue
generated from the scanner enhancements and from new applications of the scanner
until June 2009. We also have the right to finance Longport's cost of producing
its scanners in exchange for 50% of the gross revenue generated by those
scanners. In April 1999, we purchased 350,000 shares of Longport's common stock,
representing approximately 2% of its outstanding shares, for $350,000.
Employees
At December 31, 1999, we had four full time employees, including our
executive officers.
23
<PAGE>
Facilities
We sublease from Purchase Plus Buyers Group, Inc., an affiliate,
approximately 1,567 square feet of executive office space on a month-to-month
basis in Westerville, Ohio, for $1,639 per month. We believe the lease terms are
fair, reasonable and consistent with lease terms offered by nonaffiliates in the
same market area. We further believe that the office space is suitable for our
current needs and that we carry adequate insurance coverages on the premises.
24
<PAGE>
OUR MANAGEMENT
Officers and Directors
Information concerning each of our executive officers and directors is set
forth below:
Name Age Position
- ---- --- --------
Nicholas G. Venetis 49 Chief Executive Officer, President
and Director
Cleone W. Armold 49 Secretary and Director
Donald M. Pedersen 30 Chief Financial Officer and Director
Paul D. Martin 53 Director
Charles R. Bruce 49 Director
Directors hold office for a period of one year from their election at the
annual meeting of stockholders or until their successors are duly elected and
qualified. Officers are elected by, and serve at the discretion of, the board of
directors. Our audit committee consists of Messrs. Venetis and Bruce.
Nicholas G. Venetis joined us as our Chief Executive Officer, President and
a director in September 1999. From January 1995 to September 1999, he was
President, Chief Executive Officer and a director of Micrys, Inc., a
privately-held company engaged in the business of semiconductor design. Mr.
Venetis earned a BS degree in Business Administration, with a major in
accounting, from The Ohio State University. He has over 17 years of senior
management experience in business startups, corporate finance and as an
executive officer and director of a public company. His business experience
includes implementation and management of worldwide product distribution,
strategic investments, joint ventures, product development and license
agreements with a number of multinational corporations.
Cleone W. Armold joined us as our Secretary and a director in April 1999.
Since 1997, Ms. Armold has been Vice President of Operations for Purchase Plus,
an affiliate, and from 1986 to 1994, was Vice President of Con-Trak Development
Corporation, an Ohio-based construction company. She has also been Chief
Executive Officer of Simba Financial, Inc. a privately held investment company
since 1994. She earned an associate degree from Brigham Young University.
Donald M. Pedersen joined us as our Chief Financial Officer and a director
in November 1999. From 1996 to July 1999, he was Vice President of Finance for
JD Services, a privately-held telecommunications company, where he acted as the
company's senior financial officer, responsible for managing the accounting
departments, legal and accounting compliance matters, including preparing the
company for an initial public offering, negotiations with investment bankers and
development of corporate strategies. From 1989 to 1996, Mr. Pedersen was the
Chief Financial Officer and Chief Operating Officer of PAAC, Inc., a nonprofit
corporation engaged in environmental improvement projects. He earned a B.A.
degree in finance from the University of Utah and an MBA degree from the
University of Phoenix. Mr. Pedersen devotes approximately 10% of his time to the
Company's affairs.
25
<PAGE>
Paul D. Martin joined us as a director in June 1999. Since 1994, he has
been Chief Financial Officer of the Mid-Rivers market area for AON, a
multinational insurance brokerage firm. From 1987 to 1992, he was the Chief
Operating Officer of Willis Corrdon, an international insurance brokerage firm,
and from 1979 to 1981, he was Chief Executive Officer of Reliable Insurance
Company, a Missouri-based life insurance provider. He earned a B.S. degree from
the University of Missouri.
Charles R. Bruce joined us as a director in July 1999. Since July 1999, he
has been Chief Executive Officer of Nubix Corp., a franchise and marketing
company owned by Everett Eugene Armold, the husband of Cleone W. Armold. From
1994 to June 1999, he was Vice President of International Marketing for Wendy's
and from 1986 to 1994 was Vice President of Marketing for the International
Pizza Hut Franchise Holders Association. From 1978 to 1986, he was Export Sales
and Marketing Manager for The Coleman Company. He earned a B.A. degree from
Kansas State University.
Advisory Board
Our Advisory Board consists of the following individuals:
Mary Dyson. Mary Dyson is Emeritus Reader in the Biology of Tissue Repair
at the University of London. She is also a visiting professor in the School of
Health Sciences of the University of Ulster. Ms. Dyson joined the Department of
Anatomy at Guy's Hospital Medical School as a Research Associate in 1964, became
a Lecturer in 1970, a Senior Lecturer in 1975, a Reader in 1987 and an Emeritus
Reader in 1998. She is the author of over 100 research publications in
peer-reviewed journals, is one of the editors of the 37th and 38th editions of
Gray's Anatomy and has contributed to textbooks on wound healing, physiotherapy
and ultrasound. She is a member of the editorial board of a number of healthcare
related journals and has presented over 220 lectures in Europe and North America
on topics which include diagnostic and therapeutic ultrasound, electrotherapy,
wound healing, tissue repair and regeneration, and injury and repair-related
aspects of sports medicine. Ms. Dyson holds a Bachelor of Science degree and a
Ph.D. degree in biology from Bedford College at the University of London. She is
the Director of Research and Development for Longport, Inc., one of our contract
partners, and is expected to provide us assistance in connection with the
development of the Longport digital scanner.
Courtney H. Lyder. Courtney H. Lyder has been an Associate Professor of
Geriatric Nursing and Gerontology at the Yale University School of Nursing since
1994. From 1991 to 1994, Dr. Lyder was an Assistant Professor of Gerontological
Nursing and family nurse practitioner programs at St. Xavier University School
of Nursing. He is the author of numerous scientific articles on skin and wound
care and scientific presentations on wound care and nursing. Dr. Lyder has also
been the recipient of project funding for a number of research projects
involving skin and wound care. He earned Bachelor of Science, Master of Science
and Doctor of Nursing degrees from Rush University College of Nursing and a
Bachelor of Arts degree from Beloit College majoring in psychology and nursing.
Dimitrios G. Spigos. Dimitrios G. Spigos has been a professor and the
chairman of the Department of Radiology of Ohio State University since 1992.
From 1986 to 1992, he was chairman of the Department of Radiology for Cook
County Hospital, and from 1982 to 1990, was also a professor of Radiology at the
University of Illinois. He is the author of over 120 medical book chapters on
26
<PAGE>
radiology and related medical subjects and has presented almost 100 abstracts at
scientific conventions and seminars throughout the world. He has also been
invited to speak at more than 120 medical departmental seminars and meetings
since 1976. Dr. Spigos received his M.D. degree from the University of Athens,
interned at Mount Sinai Hospital in Chicago and was a resident in radiology at
the University of Illinois.
Executive Compensation
None of our executive officers or directors were paid compensation for
services in 1998. We have not signed employment agreements with any of our
executive officers. We began paying salaries to our executive officers in
September 1999. None of our executive officers is expected to receive total
compensation in excess of $100,000 during 1999.
Our outside directors receive $250 for each Board meeting attended, are
reimbursed for out-of-pocket expenses in attending board meetings and may be
issued stock options in the future on an annual basis as compensation for
serving as directors. We have no plans to issue any other form of compensation
to officers or directors, other than officers' salaries.
Stock Option Plan
We have a stock option plan which provides for the grant of options
intended to qualify as "nonqualified stock options" within the meaning of
Section 422 of the United States Internal Revenue Code of 1986 (the "Code").
The purposes of the plan are to attract and retain the best available
personnel, to provide additional incentives to our employees and to promote the
success of our business.
We have reserved 1,000,000 shares of common stock for issuance under the
plan, which is administered by our board of directors. To date, no stock options
have been issued. Under the plan, the board determines which individuals will
receive options, the time period during which the options may be partially or
fully exercised, the number of shares of common stock that may be purchased
under each option and the option price.
The per share exercise price of the common stock subject to options must
not be less than the fair market value of the common stock on the date the
option is granted. The stock options are subject to anti-dilution provisions in
the event of stock splits, stock dividends and the like.
No stock options are transferable by an optionee other than by will or the
laws of descent and distribution, and during the lifetime of an optionee, the
option is only exercisable by the optionee. The exercise date of an option
granted under the plan must not be later than ten years from the date of grant.
Any options that expire unexercised or that terminate upon an optionee's ceasing
to be employed by us will become available once again for issuance. Shares
issued upon exercise of an option rank equally with other shares then
outstanding. To date, no options have been granted under the plan.
27
<PAGE>
OUR PRINCIPAL STOCKHOLDERS
The following table sets forth certain information regarding the holdings
of common stock by (1) each person who holds of record or is known by us to hold
beneficially or of record, more than 5% of our common stock, (2) each executive
officer and director, and (3) all officers and directors as a group. The address
of each person is in care of our address at 929 Eastwind Drive, Suite 225,
Westerville, Ohio 43081.
<TABLE>
<CAPTION>
Percent Percent
Shares of Class of Class
Name Owned Prior to Offering After Offering
---- ----- ----------------- --------------
<S> <C> <C> <C>
Nicholas G. Venetis 300,000 2.5% 2.0%
Cleone W. Armold 9,528,448 80.5% 64.2%
Donald M. Pedersen -0- 0 % 0 %
Paul D. Martin 34,483 .3% .2%
Charles R. Bruce 8,621 .1% .1%
All executive officers and
directors as a group
(5 persons) 9,871,552 83.4% 66.5%
</TABLE>
RELATED PARTY AND OTHER MATERIAL TRANSACTIONS
In July 1999 we entered into an agreement with Purchase Plus, a network
marketing company owned by Everett Eugene Armold, under which Purchase Plus has
agreed it will purchase 100,000 of our discount cards for $40 per card in 2000
and will prepay the first 10,000 cards in consideration of our agreement not to
offer our discount cards to any other network marketing organization. Everett
Eugene Armold, who controls Purchase Plus, is the husband of Cleone W. Armold,
one of our directors. Two of our officers and directors, Ms. Armold and Mr.
Pedersen, are also officers and directors of Purchase Plus.
In April 1999, we purchased 350,000 shares of Longport, Inc. common stock
for $1.00 per share. The quoted market price of these shares at September 30,
1999 was $2.69 per share or a total of $940,450. In June 1999 we entered into an
agreement with Longport under which we agreed to provide to Longport $5 million
over a five-year period to fund technology enhancements for Longport's digital
scanner in exchange for 10% of the gross revenue generated from the scanner
enhancements and related new technology until 2009. We also have the right to
finance the manufacture of scanners in exchange for 50% of the revenue generated
by those scanners. There are no other affiliations or arrangements between
Longport and us.
We lease 1,567 square feet of office space from Purchase Plus Buyers Group,
Inc. on a month-to-month lease for $1,639 per month.
Between April and September, 1999 Everett Eugene Armold and Cleone W.
Armold gratuitously contributed an aggregate of $659,033 to our capital
In October 1999, Simba Financial Incorporated, a company in which Mr.
Armold is a principal stockholder, provided us with a $500,000 line of credit to
finance our operating expenses and working capital. Funds advanced under the
line of credit will bear interest at 10% per annum and are due for repayment on
December 31, 2000. As of this date, no funds have yet been advanced to us under
the line of credit.
In our opinion, the transactions described above were on terms no less
favorable than those which could have been obtained from unaffiliated third
parties. All future related party transactions will be approved by a majority of
disinterested directors.
28
<PAGE>
DESCRIPTION OF OUR SECURITIES
Units
Each unit consists of one share of common stock and one redeemable warrant.
Common Stock
We are authorized to issue 100,000,000 shares of $.001 par value common
stock, of which 11,839,827 shares are currently outstanding. Each share of
common stock is entitled to one vote on all matters submitted to a vote of the
stockholders, and cumulative voting is not permitted. Upon issuance, shares of
common stock are not subject to further assessment or call. Subject to the prior
rights of any series of preferred stock that may be issued by us in the future,
holders of common stock are entitled to receive ratably such dividends that may
be declared by the board of directors out of funds legally available therefor
and are entitled to share ratably in all assets remaining after payment of
liabilities in the event of our liquidation, dissolution or winding up. Holders
of common stock have no preemptive rights or rights to convert their common
stock into any other securities. The outstanding common stock is fully paid and
nonassessable.
We have not paid dividends on our common stock since inception and do not
plan to pay dividends in the foreseeable future. Any earnings will be retained
to finance growth.
Redeemable Warrants
Each warrant represents the right to purchase one share of common stock at
an initial exercise price of $5.00 per share until December 31, 2002. The
exercise price and the number of shares issuable upon exercise of the warrants
are subject to adjustment in certain events, including the issuance of common
stock as a dividend on shares of common stock, subdivisions or combinations of
the common stock or similar events. The warrants do not contain provisions
protecting against dilution resulting from the sale of additional shares of
common stock for less than the exercise price of the warrants or the current
market price of common stock.
Warrants may be redeemed, in whole or in part, at our option, upon 30 days'
notice, at a redemption price equal to $.01 per warrant if the closing price of
our common stock is at least $6.00 per share or more for ten consecutive trading
days.
Holders of warrants may exercise them only if a current prospectus relating
to the underlying common stock is then in effect and only if the shares are
qualified for sale, or deemed to be exempt from qualification, under applicable
state securities laws.
The shares of common stock issuable on exercise of the warrants will be,
when issued, fully paid and non-assessable. The holders of the warrants have no
rights as stockholders until they exercise their warrants.
29
<PAGE>
Preferred Stock
Our articles of incorporation authorize the issuance of up to 1,000,000
shares of no par value preferred stock with such rights and preferences as may
be determined from time to time by our board of directors. Accordingly, under
the articles of incorporation, the board of directors may, without stockholder
approval, issue preferred stock with dividend, liquidation, conversion, voting,
redemption or other rights which could adversely affect the voting power or
other rights of the holders of the common stock. The issuance of any shares of
preferred stock having rights superior to those of the common stock may result
in a decrease of the value or market price of the common stock and could further
be used by the board of directors as a device to prevent a change in our
control. We have no other anti-takeover provisions in our articles of
incorporation or bylaws. Holders of the preferred stock may have the right to
receive dividends, certain preferences in liquidation and conversion rights.
Shares Eligible for Future Sale
Prior to this offering, there has been no public market for our common
stock. Future sales of substantial amounts of common stock in the public market
could adversely affect prevailing market prices.
Upon completion of this offering, we will have outstanding 14,839,827
shares of common stock. Of these shares, the 3,000,000 shares sold in the
offering will be freely tradable without restriction under the Securities Act,
unless purchased by our "affiliates" as that term is defined in Rule 144 under
the Securities Act, generally, our officers, directors or 10% stockholders.
The remaining 11,839,827 shares outstanding are "restricted securities"
within the meaning of Rule 144 under the Securities Act. Restricted securities
may be sold in the public market only if registered or if they qualify for an
exemption from registration under Rule 144 of the Securities Act. A total of
11,474,310 shares may be sold under Rule 144 between March and July 2000, and
the remaining 365,517 shares may be sold commencing November 2000. Sales of
restricted securities in the public market, or the availability of such
securities for sale, could adversely affect the market price of the common
stock.
In general, under Rule 144, a person who has beneficially owned restricted
securities for at least one year would be entitled to sell within any
three-month period a number of shares that does not exceed the greater of one
percent of the number of shares of common stock then outstanding, which will
amount to 148,398 shares immediately after the offering, or the average weekly
trading volume of the common stock during the four calendar weeks preceding the
sale. Sales under Rule 144 are also subject to certain manner of sale provisions
and notice requirements and to the availability of current public information
about us. Under Rule 144(k), a person who is not deemed to have been our
affiliate at any time during the three months preceding a sale, and who has
beneficially owned the shares proposed to be sold for at least two years, is
entitled to sell these shares without complying with the manner of sale, public
information, volume limitation or notice provisions of Rule 144.
Transfer Agent
Corporate Stock Transfer, Inc., Denver, Colorado, is our transfer agent.
The transfer agent's address is 3200 Cherry Creek Drive South, #430, Denver,
Colorado 80209, and its telephone number is (303) 282-4800.
30
<PAGE>
Limitation on Liability
Our bylaws provide our directors, officers, employees and agents with
substantial protection against personal liability related to actions taken in
their capacity as our representatives. The effect of these provisions is that we
may be required to pay reasonably incurred expenses such as attorney's fees,
judgments, penalties, fines and amounts paid in settlements associated with work
related actions, suits or proceedings. We must pay these expenses if we find
that the individual acted in good faith and in our best interests.
PLAN OF DISTRIBUTION
We are offering a minimum of 1,000,000 units and a maximum of 3,000,000
units on a best efforts basis directly to the public through our officers and
directors, as well as through securities brokers-dealers who are members of the
NASD. Solicitation by our officers and directors will be limited to speaking at
informational meetings, attending meetings with broker-dealers and responding to
questions posed by potential investors and broker-dealers. Our officers and
directors will not receive any compensation for assisting us with the offering,
but NASD members will receive a commission of $.30 for each unit sold. No
broker-dealer has agreed to participate in the offering as of the date of this
prospectus.
We may provide NASD members who participate in the offering with a list of
persons whom we believe may be interested in purchasing units. These NASD
members may sell a portion of the units to such persons.
Upon sale of the minimum 1,000,000 units, we will apply to list our common
stock and warrants, but not our units, on the Electronic Bulletin Board under
the symbols "HLNK" for our common stock and "HLNKW" for our warrants. Unless and
until the securities are accepted for listing, no public market will develop for
the resale of the securities.
Prior to this offering, there has been no market for our securities.
Accordingly, the public offering price for the units was determined solely by
us. Among the factors we considered in determining the public offering price
were our record of operations, our current financial condition, our future
prospects, the background of our management and the general condition of the
equity securities market.
Method of Subscribing
Persons may subscribe by completing and returning our subscription
agreement. The offering price of $3.00 per unit must accompany the subscription
agreement. The minimum purchase is 100 units for $300. Certificates for the
units subscribed will be issued within three business days following the closing
of the offering.
Selling Period
The selling period of the offering will terminate 90 days from the date of
this prospectus unless extended for up to an additional 60 days, or on such
earlier date as we shall determine in our discretion.
Minimum-Maximum and Escrow
Until the minimum 1,000,000 units are sold, all funds will be deposited in
a non-interest bearing escrow account at Bank One, 701 Brooksedge Plaza Dr.,
Westerville, Ohio 43081. In the event that 1,000,000 units are not sold during
the 90-day selling period, which may be extended for an additional 60 days, all
31
<PAGE>
funds will be returned to investors without deduction or interest. If 1,000,000
units are sold, we may either continue the offering for the remainder of the
selling period or close the offering at any time.
Right to Reject
We reserve the right to reject any subscription, and to withdraw the
offering at any time prior to acceptance of the subscriptions received, if
acceptance of a subscription would result in the violation of any laws to which
we are subject.
Pursuant to Regulation M under the Securities Act, some persons
participating in the offering may engage in transactions, including stabilizing
bids or syndicate covering transactions that may have the effect of stabilizing
or maintaining the market price of the securities at a level above that which
might otherwise prevail in the open market. A "stabilizing bid" is a bid for or
the purchase of securities on behalf of an underwriter or syndicate member for
the purpose of fixing or maintaining the price of the securities. A "syndicate
covering transaction" is the bid for or purchase of securities on behalf of the
underwriter or syndicate member to reduce a short position incurred in
connection with the offering. There will be no impositions of penalty bids.
LEGAL MATTERS
Certain legal matters in connection with the offering will be passed upon
for us by the Law Office of Gary A. Agron, Englewood, Colorado.
EXPERTS
Our financial statements for the years ended December 31, 1998 and 1997
have been included in this prospectus in reliance on the report of Angell &
Deering, independent public accountants, as given upon the authority of said
firm as experts in accounting and auditing. Angell & Deering have not audited or
reviewed the unaudited interim financial information and have not expressed an
opinion or any other form of assurance with respect to such financial
information.
ADDITIONAL INFORMATION
We have filed with the Securities and Exchange Commission a Registration
Statement under the Securities Act of 1933, as amended, covering the common
stock and warrants. As permitted by the rules and regulations of the Commission,
this prospectus does not contain all of the information set forth in the
Registration Statement and the exhibits. For further information with respect to
our company and our securities, reference is made to the Registration Statement
and the exhibits, which may be examined without charge at the public reference
facilities maintained by the Commission at Judiciary Plaza, 450 Fifth Street
N.W., Washington, D.C. 20549, copies of which may be obtained from the
Commission upon payment of the prescribed fees.
We will be subject to the informational requirements of the Securities
Exchange Act of 1934, as amended, and will file reports, proxy statements and
other information with the Commission. Such reports, proxy statements and other
information may be inspected at the public reference facilities of the
Commission. Copies of these materials may be obtained at prescribed rates from
the Commission at its address above. The reports, proxy statements and other
information can also be inspected at the Commission's regional offices at 7
World Trade Center, Suite 300, New York, New York 10048 and at Northwestern
Atrium Center, 500 West Madison, Chicago, Illinois 60621 and on the Commission's
Web site at www.sec.gov.
We will furnish to our stockholders annual reports which will include
audited financial statements. We may also furnish to our stockholders quarterly
financial statements and other reports that may be authorized by our board of
directors.
32
<PAGE>
HEALTHLINK INTERNATIONAL, INC.
INDEX TO FINANCIAL STATEMENTS
Financial Statements Page
- -------------------- ----
Independent Auditors' Report F-2
Balance Sheets as of September 30, 1999 (unaudited) and
December 31, 1998 F-3
Statements of Operations for the nine months ended
September 30, 1999 and 1998 (unaudited) and for the years
ended December 31, 1998 and 1997 F-4
Statements of Changes in Stockholders' Equity for the
nine months ended September 30, 1999 (unaudited) and for
the years ended December 31, 1998 and 1997 F-5
Statements of Cash Flows for the nine months ended
September 30, 1999 and 1998 (unaudited) and for the years
ended December 31, 1998 and 1997 F-6
Notes To Financial Statements F-7
F-1
<PAGE>
INDEPENDENT AUDITORS' REPORT
To the Board of Directors
HealthLink International, Inc.
We have audited the accompanying balance sheet of HealthLink International, Inc.
as of December 31, 1998 and the related statements of operations, changes in
stockholders' equity and cash flows for the years ended December 31, 1998 and
1997. These financial statements are the responsibility of the Company's
management. Our responsibility is to express an opinion on these financial
statements based on our audits.
We conducted our audits in accordance with generally accepted auditing
standards. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are free of material
misstatement. An audit includes examining, on a test basis, evidence supporting
the amounts and disclosures in the financial statements. An audit also includes
assessing the accounting principles used and significant estimates made by
management, as well as evaluating the overall financial statement presentation.
We believe that our audits provide a reasonable basis for our opinion.
In our opinion, the financial statements referred to above present fairly, in
all material respects, the financial position of HealthLink International, Inc.
as of December 31, 1998 and the results of its operations and its cash flows for
the years ended December 31, 1998 and 1997 in conformity with generally accepted
accounting principles.
Angell & Deering
Certified Public Accountants
Denver, Colorado
July 30, 1999, except for Note
6 and the last two paragraphs of
Note 12 as to which the date is
October 28, 1999
F-2
<PAGE>
<TABLE>
<CAPTION>
HEALTHLINK INTERNATIONAL, INC.
BALANCE SHEETS
ASSETS
------
September 30, December 31,
1999 1998
---- ----
(Unaudited)
Current Assets:
<S> <C> <C>
Cash and cash equivalents $ 50 $ --
Accounts receivable - related entities -- 75
----------- -----------
Total Current Assets 50 75
----------- -----------
Other Assets:
Deferred offering costs 73,787 --
Marketable securities 940,450 --
----------- -----------
Total Other Assets 1,014,237 --
----------- -----------
Total Assets $ 1,014,287 $ 75
=========== ===========
LIABILITIES AND STOCKHOLDERS' EQUITY
------------------------------------
Current Liabilities:
Accounts payable - trade $ 34,100 $ --
----------- -----------
Total Current Liabilities 34,100 --
----------- -----------
Commitments and Contingencies -- --
Stockholders' Equity:
Preferred stock: no par value, 1,000,000 shares
authorized, none issued or outstanding -- --
Common stock: $.001 par value, 100,000,000 shares
authorized, 11,474,310 and 10,344,827 shares issued
and outstanding 11,474 10,345
Additional paid in capital 653,269 (10,345)
Retained earnings (deficit) (275,006) 75
Accumulated other comprehensive income 590,450 --
----------- -----------
Total Stockholders' Equity 980,187 75
----------- -----------
Total Liabilities and Stockholders' Equity $ 1,014,287 $ 75
=========== ===========
The accompanying notes are an integral
part of these financial statements.
F-3
</TABLE>
<PAGE>
<TABLE>
<CAPTION>
HEALTHLINK INTERNATIONAL, INC.
STATEMENTS OF OPERATIONS
Nine Months Ended Year Ended
September 30, December 31,
------------- ------------
1999 1998 1998 1997
---- ---- ---- ----
(Unaudited)
<S> <C> <C> <C> <C>
Net sales $ 207,998 $ 2,290 $ 8,242 $ --
Cost of sales 175,581 1,922 6,917 --
------------ ------------ ------------ ------------
Gross Profit 32,417 368 1,325 --
Operating expenses 186,371 500 1,250 --
Research and development 120,000 -- -- --
------------ ------------ ------------ ------------
Income (Loss) Before Provision
For Income Taxes (273,954) (132) 75 --
Provision for income taxes -- -- -- --
------------ ------------ ------------ ------------
Net Income (Loss) $ (273,954) $ (132) $ 75 $ --
============ ============ ============ ============
Net Income (Loss) Per Share
of Common Stock:
Basic $ (.02) $ -- $ -- $ --
Diluted $ (.02) $ -- $ -- $ --
Weighted Average Number of
Common Shares Outstanding:
Basic 11,474,310 11,474,310 11,474,310 11,474,310
Diluted 11,474,310 11,474,310 11,474,310 11,474,310
The accompanying notes are an integral
part of these financial statements.
F-4
</TABLE>
<PAGE>
<TABLE>
<CAPTION>
HEALTHLINK INTERNATIONAL, INC.
STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY
FOR THE NINE MONTHS ENDED SEPTEMBER 30, 1999 AND FOR THE YEARS ENDED DECEMBER 31, 1998 AND 1997
Accumulated
Common Stock Additional Current Years Retained Other
------------------- Paid In Comprehensive Earnings Comprehensive
Shares Amount Capital Income (Deficit) Income
------ ------ ------- ------ --------- ------
<S> <C> <C> <C> <C> <C> <C>
Balance at December 31, 1996 10,344,827 $ 10,345 $ (10,345) $ -- $ --
Net income -- -- -- $ -- -- --
----------
Total Comprehensive Income -- -- -- $ -- -- --
---------- ---------- ---------- ========== ---------- ----------
Balance at December 31, 1997 10,344,827 10,345 (10,345) -- --
Net income -- -- -- $ 75 75 --
----------
Total Comprehensive Income -- -- -- $ 75 -- --
---------- ---------- ---------- ========== ---------- ----------
Balance at December 31, 1998 10,344,827 10,345 (10,345) 75 --
Capital contributions in cash by a shareholder -- -- 659,033 -- --
Shares of common stock issued in March for services
valued at $.0029 per share (unaudited) 1,036,208 1,036 1,969 -- --
Shares of common stock issued in April, May and July
for services valued at $.029 per share (unaudited) 93,275 93 2,612 -- --
Net loss (unaudited) -- -- -- $ (273,954) (273,954) --
Other comprehensive income, net of tax:
Unrealized gain on securities (unaudited) -- -- -- 590,450 -- --
----------
Other Comprehensive Income (unaudited) -- -- -- 590,450 -- 590,450
----------
Total Comprehensive Income (unaudited) -- -- -- $ 316,496 -- --
==========
Distribution (unaudited) -- -- -- (1,127) --
---------- ---------- ----------- ---------- ----------
Balance at September 30, 1999 (unaudited) 11,474,310 $ 11,474 $ 653,269 $ (275,006) $ 590,450
========== ========== ========== ========== ==========
The accompanying notes are an integral
part of these financial statements.
F-5
</TABLE>
<PAGE>
<TABLE>
<CAPTION>
HEALTHLINK INTERNATIONAL, INC.
STATEMENTS OF CASH FLOWS
Nine Months Ended Year Ended
September 30, December 31,
------------- ------------
1999 1998 1998 1997
---- ---- ---- ----
(Unaudited)
Cash Flows From Operating Activities:
<S> <C> <C> <C> <C>
Net income (loss) $(273,954) $ (132) $ 75 $--
Adjustments to reconcile net income (loss) to net cash
(used) by operating activities:
Write off of note receivable 88,000 -- -- --
Common stock issued for services 5,710 -- -- --
Changes in operating assets and liabilities:
Accounts payable 34,100 -- -- --
--------- --------- --------- ----
Net Cash (Used) By Operating Activities (146,144) (132) 75 --
--------- --------- --------- ----
Cash Flows From Investing Activities:
(Increase) decrease in receivable from related entities 75 -- (75) --
Increase in payable to related entities -- 132 -- --
Investment in marketable securities (350,000) -- -- --
Advances to corporation (88,000) -- -- --
--------- --------- --------- ----
Net Cash (Used) By Investing Activities (437,925) 132 (75) --
--------- --------- --------- ----
Cash Flows From Financing Activities:
Contributed capital 659,033 -- -- --
Distribution to stockholders (1,127) -- -- --
Offering costs incurred (73,787) -- -- --
--------- --------- --------- ----
Net Cash Provided By Financing Activities 584,119 -- -- --
--------- --------- --------- ----
Net Increase (Decrease) in Cash and Cash Equivalents 50 -- -- --
Cash and Cash Equivalents at Beginning of Period -- -- -- --
--------- --------- --------- ----
Cash and Cash Equivalents at End of Period $ 50 $ -- $ -- $--
========= ========= ========= ====
Supplemental Disclosure of Cash Flow Information:
Cash paid during the period for:
Interest $ -- $ -- $ -- $--
Income taxes -- -- -- --
The accompanying notes are an integral
part of these financial statements.
F-6
</TABLE>
<PAGE>
HEALTHLINK INTERNATIONAL, INC.
NOTES TO FINANCIAL STATEMENTS
1. Organization and Summary of Significant Accounting Policies
-----------------------------------------------------------
Organization
------------
HealthLink International, Inc., formerly Commercial Building Systems,
Inc., (the "Company") was incorporated in Nevada on November 17, 1994.
The Company had no operations until March 1999.
The Company offers Benefit Savings Plans, which allow holders to pay
reduced prices or to receive a savings on health care and other related
products and services designed to create a healthy lifestyle. These
plans are arranged with an emphasis on health care, and leisure
programs for seniors, the handicapped, and students. Members receive a
discount benefit card, which they present for verification for
membership and point-of-purchase savings. The Company also intends to
explore numerous ventures in the health care industry.
Basis of Presentation
---------------------
The financial statements reflect the results of operations, financial
position, changes in stockholders' equity and cash flows of the
business segment that was transferred to the Company from Purchase Plus
Buyers Group, Inc. ("Purchase Plus") as if the Company were a separate
entity for all periods presented. The financial statements have been
prepared using the historical basis in the assets and liabilities and
historical results of operations related to the business segment.
Changes in additional paid in capital represent Purchase Plus's
contribution of its net investment after giving effect to the net
income (loss) of the Company plus net cash transfers to or from
Purchase Plus. The Company will begin accumulating its retained
earnings on April 1, 1999, the date on which the Agreement with
Purchase Plus is effective (Note 9).
Additionally, the financial statements include allocations of certain
Purchase Plus operating expenses relating to the business segment that
was transferred to the Company from Purchase Plus. Management believes
these allocations are reasonable. However, the costs of these services
charged to the Company are not necessarily indicative of the costs that
would have been incurred if the Company had performed these functions
using its own resources or purchased services from an unrelated third
party.
The financial statements included herein may not necessarily reflect
the results of operations, financial position, changes in stockholders'
equity and cash flows of the Company in the future or what they would
have been had it been a separate, stand-alone entity during the periods
presented.
Unaudited Interim Financial Statements
--------------------------------------
The financial statements as of September 30, 1999 and for the nine
months ended September 30, 1999 and 1998 are unaudited, however, in the
opinion of management of the Company, all adjustments (consisting
solely of normal recurring adjustments) necessary to a fair
presentation of the financial statements for the interim periods have
been made.
Marketable Securities
---------------------
Marketable securities consist of common stock. Marketable securities
are stated at market value as determined by the most recently traded
price of each security at the balance sheet date. All marketable
securities are defined as trading securities or available-for-sale
securities under the provisions of Statement of Financial Accounting
F-7
<PAGE>
HEALTHLINK INTERNATIONAL, INC.
NOTES TO FINANCIAL STATEMENTS
1. Organization and Summary of Significant Accounting Policies (Continued)
-----------------------------------------------------------------------
Marketable Securities (Continued)
---------------------------------
Standards No. ("SFAS") 115, "Accounting for Certain Investments in Debt
and Equity Securities."
Management determines the appropriate classification of its investments
in marketable securities at the time of each purchase and re-evaluates
such determination at each balance sheet date. Securities that are
bought and held principally for the purpose of selling them in the near
term are classified as trading securities and unrealized holding gains
and losses are included in earnings. Debt securities for which the
Company does not have the intent or ability to hold to maturity and
equity securities are classified as available-for-sale.
Available-for-sale securities are carried at fair value, with the
unrealized gains and losses, net of tax, reported as a separate
component of stockholders' equity. The cost of investments sold is
determined on the specific identification or the first-in, first-out
method.
Revenue Recognition
-------------------
Revenue is generally recognized on the sales of products or services
when the products are delivered or the services performed, all
substantial contractual obligations have been satisfied, and the
collection of the resulting receivable is deemed probable.
Stock-Based Compensation
------------------------
The Company adopted Statement of Financial Accounting Standard (SFAS)
No. 123, "Accounting for Stock-Based Compensation". The Company will
measure compensation expense for its stock-based employee compensation
plans using the intrinsic value method prescribed by APB Opinion No.
25, "Accounting for Stock Issued to Employees".
Long-Lived Assets
-----------------
In accordance with Statement of Financial Accounting Standards (SFAS)
No. 121, "Accounting for the Impairment of Long-Lived Assets and for
Long-Lived Assets to be Disposed Of", the Company reviews for the
impairment of long-lived assets and certain identifiable intangibles,
whenever events or changes in circumstances indicate that the carrying
value of an asset may not be recoverable. An impairment loss would be
recognized when the estimated future cash flows is less than the
carrying amount of the assets. No impairment losses have been
identified by the Company.
Income Taxes
------------
Deferred income taxes are provided for temporary differences between
the financial reporting and tax basis of assets and liabilities using
enacted tax laws and rates for the years when the differences are
expected to reverse.
Deferred Offering Costs
-----------------------
In connection with the Company's proposed public offering (Note 5),
costs incurred to complete the offering have been deferred and will be
offset against the proceeds of the offering if completed, or charged to
expense if the offering is not completed.
Net Income (Loss) Per Share of Common Stock
-------------------------------------------
As of December 31, 1997, the Company adopted Statement of Financial
Accounting Standards (SFAS) No. 128, "Earnings Per Share", which
specifies the method of computation, presentation and disclosure for
earnings per share. SFAS No. 128 requires the presentation of two
earnings per share amounts, basic and diluted.
F-8
<PAGE>
HEALTHLINK INTERNATIONAL, INC.
NOTES TO FINANCIAL STATEMENTS
1. Organization and Summary of Significant Accounting Policies (Continued)
-----------------------------------------------------------------------
Net Income (Loss) Per Share of Common Stock (Continued)
-------------------------------------------------------
Basic earnings per share is calculated using the average number of
common shares outstanding. Diluted earnings per share is computed on
the basis of the average number of common shares outstanding plus the
dilutive effect of outstanding stock options using the "treasury stock"
method.
The basic and diluted earnings per share are the same since the Company
had no options or warrants outstanding in 1998 and 1997.
Cash and Cash Equivalents
-------------------------
For purposes of the statements of cash flows, the Company considers all
highly liquid investments with a maturity of three months or less at
the date of purchase to be cash equivalents.
Estimates
---------
The preparation of the Company's financial statements in conformity
with generally accepted accounting principles requires the Company's
management to make estimates and assumptions that affect the reported
amounts of assets and liabilities and disclosure of contingent assets
and liabilities at the date of the financial statements and the
reported amount of revenues and expenses during the reporting period.
Actual results could differ from those estimates.
2. Marketable Securities
---------------------
Marketable securities are carried on the balance sheet at their market
value.
Unrealized Market
Cost Gain (Loss) Value
---- ----------- -----
As of September 30, 1999 (unaudited):
Available-for-sale securities:
Equity securities $350,000 $590,450 $940,450
-------- -------- --------
Total $350,000 $590,450 $940,450
======== ======== ========
3. Income Taxes
------------
The components of the provision for income taxes for the years ended
December 31, 1998 and 1997 are as follows:
1998 1997
---- ----
Current:
Federal $-- $--
State -- --
--- ---
Total -- --
--- ---
F-9
<PAGE>
HEALTHLINK INTERNATIONAL, INC.
NOTES TO FINANCIAL STATEMENTS
3. Income Taxes (Continued)
------------------------
Deferred:
Federal -- --
State -- --
--- ---
Total -- --
--- ---
Total Provision For Income Taxes $-- $--
=== ===
The provision (benefit) for income taxes reconciles to the amount
computed by applying the federal statutory rate to income before the
provision (benefit) for income taxes as follows:
1998 1997
---- ----
Federal statutory rate 34% 34%
State income taxes, net of federal benefits 8 8
Valuation allowance -- --
Other -- --
--- ---
Total 42% 42%
=== ===
The following is a reconciliation of the provision for income taxes to
income before provision for income taxes computed at the federal
statutory rate of 34%.
1998 1997
---- ----
Income taxes at the federal statutory rate $ 26 $--
State income taxes, net of federal benefits 6 --
Other (32) --
---- ----
Total $-- $--
==== ====
4. Accumulated Other Comprehensive Income
--------------------------------------
In June 1997, the Financial Accounting Standards Board issued Statement
of Financial Accounting Standard (SFAS) No. 130 "Reporting
Comprehensive Income" which the Company adopted in the first quarter of
1998. SFAS No. 130 requires presentation of comprehensive income and
its components in the financial statements. Components of other
comprehensive income consist of the following:
Accumulated
Unrealized Other
Gains/(Losses) Comprehensive
on Securities Income (Loss)
------------- -------------
Balance at December 31, 1996 $ -- $ --
1997 change -- --
-------- --------
Balance at December 31, 1997 -- --
1998 change -- --
-------- --------
Balance at December 31, 1998 -- --
1999 change (unaudited) 590,450 590,450
-------- --------
Balance at September 30, 1999 (unaudited) $590,450 $590,450
======== ========
F-10
<PAGE>
HEALTHLINK INTERNATIONAL, INC.
NOTES TO FINANCIAL STATEMENTS
5. Stockholders' Equity
--------------------
Amendment to Authorized Common Shares
-------------------------------------
In March 1999, the Company's Board of Directors authorized, and the
shareholders approved, an amendment of the Company's Articles of
Incorporation, to increase the number of authorized shares of common
stock from 25,000 to 100,000,000 with a par value of $.001. The Company
also authorized 1,000,000 shares of preferred stock with no par value.
In March 1999, the Company's stockholders returned their 900 shares of
common stock, representing all of the outstanding common stock of the
Company, in exchange for 30,000,000 newly issued shares of common
stock. This transaction has been accounted for as a stock split and all
share information and per share data have been retroactively restated
for all periods presented to reflect the stock split.
Initial Public Offering
-----------------------
The Company is in the process of filing a registration statement with
the Securities and Exchange Commission for an initial public offering
("IPO") of 3,000,000 units of the Company's securities at a price of
$3.00 per unit without the assistance of an underwriter. The Company is
offering a minimum of 1,000,000 units and a maximum of 3,000,000 units.
Until 1,000,000 units are sold all funds will be placed in a
non-interest bearing escrow account. If 1,000,000 units are not sold
within 90 days from the date of the Registration Statement all funds
will be returned to the investors without interest. Each unit consists
of one share of the Company's common stock and one redeemable common
stock purchase warrant. Each warrant is exercisable to purchase one
share of common stock at $5.00 per share until December 31, 2002. The
warrants may be redeemed by the Company for $.01 per warrant if the
closing price of the common stock is at least $6.00 per share for ten
consecutive trading days.
6. Stock Options and Warrants
--------------------------
Stock Option Plan
-----------------
The Company adopted a stock option plan (the "Plan"), effective as of
November 15, 1999, which provides for the grant of non-qualified stock
options. A total of 1,000,000 shares of common stock have been reserved
for issuance under the Plan.
Options under the Company's plan are issuable only to eligible
officers, directors, key employees and consultants of the Company. The
Plan is administered by a committee selected by the Board of Directors,
which determines those individuals who shall receive options, the time
period during which the options may be exercised, the number of shares
of common stock that may be purchased under each option, and the option
price. Unless sooner terminated, the Plan shall remain in effect until
December 31, 2009.
The per share exercise price of the common stock may not be less than
the fair market value of the common stock on the date the option is
granted. The stock options are subject to anti-dilution provisions in
the event of stock splits, stock dividends and the like.
No stock options are transferrable by an optionee other than by will or
the laws of descent and distribution, and during the lifetime of an
optionee, the option is only exercisable by the optionee. The exercise
date of an option granted under the Plan must not be later than ten
years from the date of grant. Any options that expire unexercised or
F-11
<PAGE>
HEALTHLINK INTERNATIONAL, INC.
NOTES TO FINANCIAL STATEMENTS
6. Stock Options and Warrants (Continued)
--------------------------------------
Stock Option Plan (Continued)
-----------------------------
that terminate upon an optionee's ceasing to be employed by the Company
will become available once again for issuance.
7. Preferred Stock
---------------
The authorized preferred stock of the Company consists of 1,000,000
shares, no par value. The preferred stock may be issued in series from
time to time with such designation, rights, preferences and limitations
as the Board of Directors of the Company may determine by resolution.
The rights, preferences and limitations of separate series of preferred
stock may differ with respect to such matters as may be determined by
the Board of Directors, including without limitation, the rate of
dividends, method and nature of payment of dividends, terms of
redemption, amounts payable on liquidation, sinking fund provisions (if
any), conversion rights (if any), and voting rights. Unless the nature
of a particular transaction and applicable statutes require approval,
the Board of Directors has the authority to issue these shares without
shareholder approval.
8. Commitments and Contingencies
-----------------------------
Technology Enhancement and Marketing Agreement
----------------------------------------------
The Company entered into a Technology Enhancement and Marketing
Agreement (the "Agreement") with a corporation in June 1999. The
Company has agreed to fund $5,000,000 for research for biomedical
technology enhancements to the corporation's digital scanner
technologies. The two companies will share in the proceeds from the
sale or lease of any enhancements and new applications of the digital
scanner developed as a result of the research funded by the Company.
The Company will receive from the corporation ten percent of the gross
revenues from the sale or lease of any enhancements and new
applications of the digital scanner developed as a result of the
research funded by the Company under the Agreement for a period of ten
years. In addition, the corporation will give the Company the
opportunity to finance up to fifty percent of the digital scanners
produced and from each digital scanner produced and financed by the
Company, the corporation and the Company will share equally in the
lease income of $2,000 per month. The Agreement is effective June 1,
1999 and the Company shall provide the funding in increments of $30,000
a month for the first year, $60,000 a month for the second year,
$120,000 a month for the third and fourth years and $100,000 a month
for the fifth year until a total of $5,000,000 is paid under the
Agreement.
The Year 2000
-------------
The Company is currently working to resolve the potential impact of the
Year 2000 on the processing of date-sensitive information by the
Company's computerized information systems. The Year 2000 problem is
the result of computer programs being written using two digits (rather
than four) to define the applicable year. Any of the Company's programs
that have time-sensitive software may recognize a date using "00" as
the year 1900 rather than the year 2000, which could result in
miscalculations or system failures. Costs of addressing potential
problems are expensed as incurred and are not expected to have a
material adverse impact on the Company's financial position, results of
operations or cash flows in future periods. However, if the Company or
its vendors are unable to resolve such processing issues in a timely
manner, it could result in a material financial risk. Accordingly, the
F-12
<PAGE>
HEALTHLINK INTERNATIONAL, INC.
NOTES TO FINANCIAL STATEMENTS
8. Commitments and Contingencies (Continued)
-----------------------------------------
The Year 2000 (Continued)
-------------------------
Company plans to devote the necessary resources to resolve all
significant Year 2000 issues in a timely manner. While the Company does
not at this time anticipate significant problems with suppliers and
customers, it has not developed Year 2000 contingency plans, other than
the review and remedial actions described above and does not intend to
do so unless it believes such plans are merited by the results of its
continuing Year 2000 review.
9. Related Party Transactions
--------------------------
The Company occupies office space which is shared by seven entities
that are related through common ownership. The Company rents the office
space on a month to month basis and is allocated one seventh of the
lease cost on a monthly basis.
The Company entered into a two year agreement with Purchase Plus in
April 1999 to purchase various benefits from Purchase Plus. In
connection with this agreement, the Company has agreed with Purchase
Plus to manage the health care benefits which Purchase Plus purchases
from an unrelated insurance company. The Company will provide these
health care benefits to Purchase Plus for $25.44 per year for each
individual that is enrolled in such programs. The Company purchases the
benefits from the insurance company utilizing Purchase Plus as the
intermediary. In the future, the Company intends to contract directly
with the insurance company to purchase the benefits.
In July 1999, the Company entered into a new two year agreement with
Purchase Plus to provide various health care benefits from the Company.
The Company will provide these health care benefits to Purchase Plus
for $32.35 per year for each individual that is enrolled in such
programs. The Company purchases the benefits directly from insurance
companies and other providers under the terms of the new agreement.
The Company has an account receivable from Purchase Plus of $75 at
December 31, 1998.
10. Concentration of Credit Risk
----------------------------
Financial instruments which potentially subject the Company to
concentrations of credit risk consist principally of temporary cash
investments and accounts receivable. The Company places its cash
equivalents and short term investments with high credit quality
financial institutions and limits its credit exposure with any one
financial institution. The Company provides credit in the normal course
of business. The Company performs periodic credit evaluations of its
customers' financial condition and generally requires no collateral.
The Company maintains reserves for potential credit losses, and such
losses have not exceeded management's expectations.
11. Fair Value of Financial Instruments
-----------------------------------
Disclosures about Fair Value of Financial Instruments for the Company's
financial instruments are presented in the table below. These
calculations are subjective in nature and involve uncertainties and
significant matters of judgment and do not include income tax
considerations. Therefore, the results cannot be determined with
precision and cannot be substantiated by comparison to independent
market values and may not be realized in actual sale or settlement of
the instruments. There may be inherent weaknesses in any calculation
technique, and changes in the underlying assumptions used could
F-13
<PAGE>
HEALTHLINK INTERNATIONAL, INC.
NOTES TO FINANCIAL STATEMENTS
11. Fair Value of Financial Instruments (Continued)
-----------------------------------------------
significantly affect the results. The following table presents a
summary of the Company's financial instruments as of December 31, 1998:
1998
--------------------
Carrying Estimated
Amount Fair Value
------ ----------
Financial Assets:
Cash and cash equivalents $-- $--
Marketable securities -- --
The carrying amounts for cash and cash equivalents, receivables,
accounts payable and accrued expenses approximate fair value because of
the short maturities of these instruments. The fair value of marketable
securities is determined by the most recently traded price of each
security at the balance sheet date.
12. Subsequent Events
-----------------
Issuance of Common Stock
------------------------
In March through July 1999, the Company issued 1,129,483 shares of
common stock in consideration for services valued at $.0029 to $.029
per share of common stock.
Stock Split
-----------
On October 28, 1999, the Company's shareholders adopted a resolution
approving a 2.90 for one reverse stock split of the issued and
outstanding common shares, effective October 28, 1999. All share
information and per share data have been retroactively restated for all
periods presented to reflect the stock split.
Financing Commitment
--------------------
In October 1999, Simba Financial, Incorporated, a company controlled by
the owner of Purchase Plus, provided the Company with a $500,000 line
of credit to finance the Company's operating expenses and working
capital requirements. Amounts advanced under the line of credit will
bear interest at 10% per annum and are due on December 31, 2000.
F-14
<PAGE>
================================================================================
HEALTHLINK INTERNATIONAL, INC.
[GRAPHIC OMITTED]
Until , 2000 (25 days after the date of this prospectus), all dealers that
buy, sell or trade these securities, whether or not participating in this
offering, may be required to deliver a prospectus. This is in addition to the
dealers' obligation to deliver a prospectus when acting as underwriters and with
respect to their unsold allotments or subscriptions.
================================================================================
<PAGE>
PART II
INFORMATION NOT REQUIRED IN PROSPECTUS
ITEM 24. INDEMNIFICATION OF DIRECTORS AND OFFICERS.
Article VII of the Registrant's bylaws provides as follows:
"ARTICLE VII INDEMNIFICATION
PURSUANT TO N.R.S. 78.751 any person who is a Director, Officer, Employee,
or Agent of this Corporation, who becomes a party to an action is entitled to
indemnification against expenses including attorney fees, judgments, fines and
amounts paid in settlement, if he acted in good faith and he reasoned his
conduct or action to be in the best interest of the Corporation."
ITEM 25. OTHER EXPENSES OF ISSUANCE AND DISTRIBUTION (1)
SEC Registration Statement............................... $ 7,080
Blue Sky Filing Fees..................................... $ 10,000
Blue Sky Legal Fees...................................... $ 20,000
Printing Expenses........................................ $ 30,000
Legal Fees and Expenses.................................. $ 120,000
Accounting Fees.......................................... $ 45,000
Transfer Agent Fees...................................... $ 5,000
Miscellaneous Expenses................................... $ 62,920
---------
Total $ 300,000
=========
(1) All expenses, except the SEC registration fee and NASD filing fee, are
estimated.
ITEM 26. RECENT SALES OF UNREGISTERED SECURITIES
During the last three years, the Registrant sold the following securities
which were not registered under the Securities Act, as amended.
(i) In March 1999, the Registrant sold the following shares of its common stock
to the persons listed below for $.0029 per share or a total of $3,005.
II-1
<PAGE>
Name Number of Shares
---- ----------------
Golden Guardian Productions, Ltd. 182,759
Agape Family Trust 103,448
Harmony International, LLC 68,966
Janitye L. Vaile 172,414
Hubert T. McDonald, LLC 103,448
M.E.I.C. 75,862
Chris Beddoes 34,483
Ronald Beddoes 34,483
David Martin 34,483
Dan Beddoes 17,241
Alan Day 17,241
Don Fisher 17,241
Kevin Grandy 17,241
Ruthie Lewis 17,241
Lisa Navaratnam 17,241
Frank Valinho 17,241
Joe Valinho 17,241
Jim Williamson 17,241
Lynn Harrison 10,345
Elizabeth Blair 8,621
Amy Kish 8,621
William Lundberg 8,621
Becky Breedlove 6,897
Bill Fate 6,897
Patricia Morgan 6,897
Tanya St. John 6,897
Don Wright 6,897
(ii) Between April and July, 1999, the Registrant sold the following shares of
its common stock to the persons listed below for $.029 per share or a total of
$2,705.
Kris TenEyck, LLC 29,310
Victor E. Vaile, IV, LLC 29,310
David Thomas, LLC 12,758
Charles Bruce 8,621
ETN, Inc. 6,897
Brenda Burns 3,448
Shelly Blake 2,931
(iii) In November 1999, the Registrant sold 300,000 shares to Nicholas G.
Venetis and 65,517 shares to Chris Beddoes for $1.50 per share, or a total of
$548,276.
II-2
<PAGE>
With respect to the sales made, the Registrant relied on Section 4(2) of
the Securities Act of 1933, as amended (the "Securities Act"). No advertising or
general solicitation was employed in offering the securities. The securities
were offered to a limited number of persons all of whom were sophisticated
investors who were business associates or personal friends of the Registrant or
its stockholders, executive officers or directors, and the transfer thereof was
appropriately restricted by the Registrant. All persons were capable of
analyzing the merits and risks of their investment,acknowledged in writing that
they were acquiring the securities for investment and not with a view toward
distribution or resale and understood the speculative nature of their
investment. All persons were provided information regarding the Registrant,
including a description of its proposed business. Officers of the Registrant
answered all questions raised by these persons.
ITEM 27. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES
Exhibit No. Title
- ----------- -----
1.01 Form of Selling Agreement (To be filed by Amendment)
1.02 Form of Indication of Interest Card (To be filed by Amendment)
1.03 Form of Subscription Agreement (1)
3.01 Articles of Incorporation, as amended, of the Registrant (1)
3.02 Bylaws of the Registrant (1)
5.01 Opinion of Gary A. Agron regarding legality of the common stock
and warrants (includes consent) (1)
10.01 Agreement with Longport, Inc. (1)
10.02 Agreement with Purchase Plus Buyers Group, Inc. (1)
10.03 Agreement with International MedCare, Inc.(1)
10.05 Line of credit with Simba Financial Incorporated (1)
10.06 Agreement with National Administrative Company, Inc. (1)
10.07 Stock Option Plan (1)
23.01 Consent of Gary A. Agron (included in Exhibit 5.01) (1)
23.02 Consent of Angell & Deering (1)
23.03 Consent of Angell & Deering
27.01 Financial Data Schedule (1)
27.02 Financial Data Schedule
- ------------
(1) Previously Filed
ITEM 28. UNDERTAKINGS.
The Registrant hereby undertakes:
(a) That insofar as indemnification for liabilities arising under the
Securities Act may be permitted to directors, officers and controlling
persons of the Registrant, the Registrant has been advised that in the
opinion of the Securities and Exchange Commission, such indemnification is
against public policy as expressed in the Act and is, therefore,
unenforceable. In the event that a claim for indemnification against such
liabilities (other than the payment by the Registrant of expenses incurred
or paid by a director, officer or controlling person of the Registrant in
the successful defense of any action, suit or proceeding) is asserted by
such director, officer or controlling person in connection with the
securities being registered, the Registrant will, unless in the opinion of
its counsel the matter has been settled by controlling precedent, submit to
a court of appropriate jurisdiction the question of whether such
indemnification by it is against public policy as expressed in the Act and
will be governed by the final adjudication of such issue.
II-3
<PAGE>
(b) That subject to the terms and conditions of Section 13(a) of the
Securities Exchange Act of 1934, it will file with the Securities and
Exchange Commission such supplementary and periodic information, documents
and reports as may be prescribed by any rule or regulation of the
Commission heretofore or hereafter duly adopted pursuant to authority
conferred in that section.
(c) That any post-effective amendment filed will comply with the
applicable forms, rules and regulations of the Commission in effect at the
time such post-effective amendment is filed.
(d) To file, during any period in which offers or sales are being
made, a post-effective amendment to this registration statement:
(i) To include any prospectus required by section 10(a)(3) of the
Securities Act;
(ii) To reflect in the prospectus any facts or events arising
after the effective date of the registration statement (or the most
recent post-effective amendment thereof) which, individually or in the
aggregate, represent a fundamental change in the information set forth
in the registration statement;
(iii) To include any material information with respect to the
plan of distribution not previously disclosed in the registration
statement or any material change to such information in the
registration statement;
(e) That, for the purpose of determining any liability under the
Securities Act, each such post-effective amendment shall be deemed to be a
new registration statement relating to the securities offered therein, and
the offering of such securities at that time shall be deemed to be the
initial bona fide offering thereof.
(f) To remove from registration by means of a post-effective amendment
any of the securities being registered which remain unsold at the
termination of the Offering.
(g) To provide at the closing of the offering certificates in such
denominations and registered in such names as required to permit prompt
delivery to each purchaser.
II-4
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Act, as amended, the
Registrant certifies that it has reasonable grounds to believe that it meets all
of the requirements of filing on Form SB-2 and has duly caused this registration
statement to be signed on its behalf by the undersigned, hereunto duly
authorized, in Westerville, Ohio, on January 10, 2000.
HEALTHLINK INTERNATIONAL, INC.
By: /s/ Nicholas G. Venetis
----------------------------------------
Nicholas G. Venetis, Chief Executive Officer
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature
appears below constitutes and appoints Nicholas G. Venetis, as his true and
lawful attorney-in-fact and agent, with full power of substitution and
resubstitution, for him and in his name, place and stead, in any and all
capacities, to sign any and all amendments (including post-effective amendments)
to this Registration Statement, and to file the same, with all exhibits thereto,
and other documents in connection therewith, with the Securities and Exchange
Commission, granting unto said attorney-in-fact and agent, full power and
authority to do and perform each and every act and thing requisite and necessary
to be done in connection therewith, as fully to all intends and purposes as he
might or could do in person, hereby ratifying and confirming all that said
attorney-in-fact and agent, or his substitute or substitutes, may lawfully do or
cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act, as amended, this
Registration Statement has been signed below by the following persons on the
dates indicated.
Signature Title Date
--------- ----- ----
/s/ Nicholas G. Venetis Chief Executive Officer, January 10, 2000
- ------------------------ President and Director
Nicholas G. Venetis
/s/ Cleone W. Armold Secretary and Director January 10, 2000
- ------------------------
Cleone W. Armold
/s/ Donald M. Pedersen Chief Financial Officer January 10, 2000
- ------------------------ (Principal Accounting
Donald M. Pedersen Officer) and Director
/s/ Paul D. Martin Director January 10, 2000
- ------------------------
Paul D. Martin
/s/ Charles R. Bruce Director January 10, 2000
- ------------------------
Charles R. Bruce
II-5
<PAGE>
HEALTHLINK INTERNATIONAL, INC.
EXHIBIT INDEX
Exhibit No. Title
- ----------- -----
1.01 Form of Selling Agreement (To be filed by Amendment)
1.02 Form of Indication of Interest Card (To be filed by
Amendment)
1.03 Form of Subscription Agreement (1)
3.01 Articles of Incorporation, as amended, of the Registrant (1)
3.02 Bylaws of the Registrant (1)
5.01 Opinion of Gary A. Agron regarding legality of the common stock
and warrants (includes consent) (1)
10.01 Agreement with Longport, Inc. (1)
10.02 Agreement with Purchase Plus Buyers Group, Inc. (1)
10.03 Agreement with International MedCare, Inc. (1)
10.05 Line of credit with Simba Financial Incorporated (1)
10.06 Agreement with National Administrative Company, Inc. (1)
10.07 Stock Option Plan (1)
23.01 Consent of Gary A. Agron (included in Exhibit 5.01) (1)
23.02 Consent of Angell & Deering (1)
23.03 Consent of Angell & Deering
27.01 Financial Data Schedule (1)
27.02 Financial Data Schedule
- ---------------
(1) Previously Filed
CONSENT OF INDEPENDENT CERTIFIED PUBLIC ACCOUNTANTS
We hereby consent to the use, in Amendment No. 1 to the Registration Statement
on Form SB-2, of our reort dated July 30, 1999 except for Note 6 and the last
two paragraphs of Note 12 as to which the date is October 28, 1999 relating to
the financial statements of HealthLink International, Inc. for the years ended
December 31, 1998 and 1997 and the reference to our firm under the caption
"Experts" in the Prospectus contained in said Registration Statement.
Angell & Deering
Certified Public Accountants
Denver, Colorado
January 10, 2000
<TABLE> <S> <C>
<ARTICLE> 5
<S> <C>
<PERIOD-TYPE> 9-MOS
<FISCAL-YEAR-END> DEC-31-1999
<PERIOD-END> SEP-30-1999
<CASH> 50
<SECURITIES> 0
<RECEIVABLES> 0
<ALLOWANCES> 0
<INVENTORY> 0
<CURRENT-ASSETS> 50
<PP&E> 0
<DEPRECIATION> 0
<TOTAL-ASSETS> 1,014,287
<CURRENT-LIABILITIES> 34,100
<BONDS> 0
0
0
<COMMON> 11,474
<OTHER-SE> 968,713
<TOTAL-LIABILITY-AND-EQUITY> 1,014,287
<SALES> 207,998
<TOTAL-REVENUES> 207,998
<CGS> 175,581
<TOTAL-COSTS> 306,371
<OTHER-EXPENSES> 0
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> 0
<INCOME-PRETAX> (273,954)
<INCOME-TAX> 0
<INCOME-CONTINUING> 0
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> (273,954)
<EPS-BASIC> (.02)
<EPS-DILUTED> (.02)
</TABLE>
